

Final Program

3rd World Psoriasis & Psoriatic Arthritis Conference 2012

“Psoriasis – a global health challenge”
June 27–July 1, 2012 in Stockholm, Sweden



Photo: Ola Ericson/imagebank.sweden.se



INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS

www.ifpa-pso.org

Conference mission

To impart current scientific and clinical care information about psoriasis and psoriatic arthritis to medical professionals, industry representatives and patient associations so they can collaborate to develop an international agenda to improve the understanding of psoriasis and psoriatic arthritis and access to care throughout the world.

Conference Objectives

- Bring medical professionals, industry representatives and national psoriasis association representatives from around the world together to examine current information about psoriasis and psoriatic arthritis.
- Encourage collaboration on developing future research and advocacy initiatives.
- Increase the global recognition of the seriousness of these diseases.
- Improve the quality of life of people who have psoriasis and psoriatic arthritis.
- Develop a broader international perspective of psoriasis and psoriatic arthritis.
- Increase medical professionals' awareness of the value of nonprofit psoriasis associations, the role they play in assisting the medical communities and the value in supporting their efforts.
- Build partnerships with the medical professionals, researchers and the pharmaceutical/biotechnology industry.

Patron of the 3rd World Psoriasis & Psoriatic Arthritis Conference




Photo: Jonas Ekströmer / Scampix

His Majesty King Carl Gustav

3rd World Psoriasis & Psoriatic Arthritis Conference 2012

Content

Welcome.....	4
– IFPA President	
– Scientific Executive Committee	
Committees	5
Contact and Conference information	5
Scientific Program	6
Social Program.....	13
Hotels and social event locations – map	15
Stockholm Waterfront Congress Centre	17
General Information.....	19
Stockholm and Sweden.....	21
Abstract Titles	22

Welcome to the 3rd World Conference

Dear Friends,

In 2012 the International Federation of Psoriasis Associations (IFPA) will be holding the World Psoriasis & Psoriatic Conference in Stockholm for the third time, in cooperation with leading dermatologists and rheumatologists. The purpose of the conference is to elucidate the disease from a number of scientific aspects. At the first conference, in 2006, the focus was on clarifying the connection between psoriasis of the skin and psoriatic arthritis. At the second conference, in 2009, we moved on to present an aggregated picture of psoriasis as a complex, chronic, inflammatory disease that can affect several of the body's organs through a number of co-morbidities.

For this upcoming conference we have even further deepened the cooperation between IFPA and the medical profession, and a number of new areas will be covered which will improve the understanding and care of psoriasis patients, such as the psychosocial impact on quality of life.

The scientific program will also, as before, be strongly influenced by IFPA's worldwide member survey, to ensure that the patient's perspective is included. As with the 2009 conference, there will also be special seminars and side tracks for nurses, allied health professionals and others who have a most important role

in the care of psoriasis patients. This complementary program is arranged in cooperation with the International Skin care Nursing Group (ISNG).

Welcome to the 3rd World Psoriasis & Psoriatic Arthritis Conference and to the brand-new Stockholm Waterfront Congress Centre!

Yours sincerely,



Lars Ettarp
President of IFPA

Dear Colleagues, Ladies and Gentlemen,

Our understanding of the spectrum of psoriatic disease has made considerable strides since the last World Psoriasis & Psoriatic Arthritis Conference, held in Stockholm in 2009. New treatments are being developed, new insights have been obtained into the pathogenesis and clinical diagnosis, and the recognition of psoriasis as a noncommunicable disease with a great disease burden has further advanced. The previous two conferences, in 2006 and 2009, were very successful in allowing researchers, clinicians and patients to keep pace with this progress, and reinforced the need to continue this type of interaction.

The 3rd World Psoriasis & Psoriatic Arthritis Conference, to be held on June 27 to July 1, 2012, will provide us with the opportunity to address and discuss a broad spectrum of topics related to psoriatic disease. Organized by the International Federation of Psoriasis Associations, IFPA, the conference will take place in Stockholm in a brand-new congress venue, Stockholm Waterfront Congress Centre. Based on surveys among the national psoriasis patient organisations, and with

the support from our colleagues on the scientific programme committee, we have developed a conference agenda with plenary lectures given by recognized experts in their field. This will ensure that relevant issues are being addressed with much practical expertise at the highest possible scientific level. Sponsored lunch seminars and satellite symposia will provide further information relevant to the clinical care and quality of life of psoriasis patients.

We are confident that with this programme we will be able to provide a lively platform for continuing medical education and scientific discussion related to psoriatic disease while allowing us all the opportunity to have open discussions with our colleagues and patients from around the world.

We look forward to seeing you in the beautiful city of Stockholm.

Yours sincerely,



Alan Menter
President of the 3rd World Psoriasis & Psoriatic Arthritis Conference

Chairman of the Scientific Executive Committee



Dafna Gladman
Co-chair of the Scientific Executive Committee



Jörg Prinz
Co-chair of the Scientific Executive Committee

Committees

Scientific Executive Committee

Alan Menter, Chairman
Dafna Gladman, Co-Chair
Jörg Prinz, Co-Chair

Scientific Program Committee

Hervé Bachelez
Jonathan Barker
Kenneth Gordon
Philip Helliwell
Arthur Kavanaugh
Alexa Kimball
Peter Nash
Proton Rahman

IFPA Scientific Advisory Board

Jörg Prinz
Peter van de Kerkhof
Mark Lebwohl
Philip Mease
Christopher Ritchlin
Mona Stähle

Organizing Committee

Chairman: Joachim Barth
IFPA Executive Committee
IFPA Secretariat

Council of Scientific Advisors

Edgardo Chouela
Enno Christophers

Luis Espinosa
Oliver FitzGerald
Amit Garg
Björn Guðbjörnsson
Arthur Kavanaugh
Peter van de Kerkhof
Mark Lebwohl
Ennio Lubrano
Neil McHugh
Philip Mease
Ignazio Olivieri
Christopher Ritchlin
Ricardo Romiti
Jean-Hilaire Saurat
Fernando Stengel
Mona Stähle
William Taylor
Gail Todd
Vermén Verrallo-Rowell

Contact and Conference information

Conference organizer

Congrex Sweden AB
Phone: +46 8 459 66 00
Fax: + 46 8 661 91 25
E-mail: psoriasis2012@congrex.com
www.congrex.com

IFPA Secretariat

Box 5173
SE-121 18 Johanneshov
SWEDEN
Phone: +46 8 556 109 14
Fax: +46 8 556 109 19
E-mail: ifpa@pso.se
www.ifpa-pso.org
http://ifpaworldconference.com

Conference venue

Stockholm Waterfront Congress Centre
Nils Ericsons Plan 4
Stockholm
Phone: +46 8 5050 6000
www.stockholmwaterfront.com

Conference opening hours

Registration desk and general information desk

Wednesday, 27 June	18.00 – 20.00
Thursday, 28 June	07.30 – 18.00
Friday, 29 June	07.00 – 19.00
Saturday, 30 June	07.00 – 17.00

Speakers' preview room

Wednesday, June 27	18.00 – 20.00
Thursday, June 28	07.30 – 18.00
Friday, June 29	07.00 – 19.00
Saturday, June 30	07.00 – 17.00

Commercial exhibition and poster exhibition

Commercial exhibition open for access by medical professionals.

Thursday, 28 June	08.00 – 17.45
Friday, 29 June	07.30 – 17.45
Saturday, 30 June	07.30 – 17.15

Registration

For questions about the social program, payment or accommodations please contact the registration desk. Please see page 15 to view the map including the official hotels.

The registration fee for participants includes

- Admission to the conference 28-30 June
- Conference documentation
- Coffee/tea
- Conference reception, June 27 (if registered)
- Reception at Stockholm City Hall, June 28 (if registered)
- Conference dinner at subsidized rate (if registered)

The registration fee for accompanying persons includes

- Conference reception, June 27 (if registered)
- Reception at Stockholm City Hall, June 28 (if registered)
- Conference dinner at subsidized rate, June 29 (if registered)



Foto: Ola Eriksson/Ingebank, sweden.se

Scientific Program

Time	GENERAL PROGRAM	Time	Complementary program
------	-----------------	------	-----------------------

Wednesday June 27

Pre-Conference meetings

Meetings of international research consortia and subcommittees

- 18.00 – 20.00** Registration for the conference opens at the Stockholm Waterfront Congress Centre
- 18.00 – 19.00** Conference reception open for all delegates at the conference venue, floor 5
- 19.00 – 20.00** Welcome program (see page 13 for more information)

Thursday June 28

07.30 Registration opens

08.15 Opening ceremony

08.40 – 10.00 **Plenary 1: Psoriatic disease, skin and joint pathogenesis**

Chairs: Jörg Prinz, Dafna Gladman

08.40 – 09.20 Molecular pathways to psoriatic skin inflammation

Speaker: James Krueger

09.20 – 10.00 Mechanisms of bone formation and destruction in psoriatic arthritis

Speaker: Christopher Ritchlin

10.00 – 10.20 **Coffee/Posters/Exhibits**

10.30 – 12.00 **Plenary 2: Psoriatic disease epidemiology**

Chairs: Jean-Hilaire Saurat, Philip Helliwell

10.30 – 10.50 Disease associations in psoriasis: indicators of systemic inflammation?

Speaker: Joel Gelfand

10.50 – 11.10 Psoriatic arthritis: Advances in phenotype and classification, what has changed since Moll and Wright?

Speaker: William Taylor

11.10 – 11.30 Psoriatic arthritis: Who has it, who gets it?

Speaker: Vinod Chandran

11.30 – 11.50 Pustular psoriasis; what is it, what makes the difference?

Speaker: Hervé Bachelez

Complementary program

Chairs: Joachim Barth, Hoseah Waweru

Please note that the Complementary program's sessions will be in hall C1-C3 located on level 2.

- 10.00** **Complementary program opens**
Welcome address by Lars Ettarp, President of IFPA
- 10.05 – 10.15 **Introduction to the complementary program**
Speaker: Joachim Barth
- 10.15 – 10.35 **Psoriasis of the skin – present knowledge**
Speaker: Peter van de Kerkhof
- 10.35 – 10.55 **Psoriatic arthritis – present knowledge**
Speaker: Philip Mease
- 10.55 – 11.15 **Comorbidities – a new important aspect of psoriasis**
Speaker: Mona Ståhle

Scientific Program

Time	GENERAL PROGRAM	Time	Complementary program
11.50 – 12.00	ABSTRACT PRESENTATION. Advanced Cardiometabolic Phenotyping in Psoriasis: Links Between Psoriasis and Cardiovascular Disease? <i>Presenter: Nehal Mehta</i>	Complementary program <i>Chairs: Joachim Barth, Hoseah Waweru</i> Please note that the Complementary program's sessions will be in hall C1-C3 located on level 2.	
12.00 – 13.30	Lunch/Posters/Exhibits		
12.15 – 13.15	INDUSTRY-SPONSORED LUNCH SEMINAR – Celgene – The dawn of change in psoriatic disease treatment	11.15 – 11.35 Factors provoking psoriasis and their prevention <i>Speaker: Mark Lebwohl</i> 11.35 – 11.55 Psychosocial burden of the disease <i>Speaker: Sylvia van Beugen</i> 11.55 – 12.15 Panel discussion	
13.30 – 15.30	Plenary 3: Psoriatic disease around the world: ethnic, geographic and therapeutic considerations <i>Chairs: Enno Christophers, Luis Espinosa</i>		
13.30 – 14.00	The psoriatic phenotypes: a global perspective <i>Speaker: Christopher Griffiths</i>		
14.00 – 14.20	Psoriatic arthritis in Latin America: challenges in diagnosis and treatment <i>Speaker: Sergio Toloza</i>		
14.20 – 14.40	Psoriasis in India: Clinical patterns and treatment challenges <i>Speaker: Sunil Dogra</i>	The Blue Hall in the Stockholm City Hall.	
14.40 – 15.00	Psoriatic arthritis in South East Asia: disease characteristics and economic burden <i>Speaker: Lai-Shan Tam</i>		
15.00 – 15.20	HIV and psoriasis: the African experience <i>Speaker: Anisa Mosam</i>		
15.20 – 15.30	ABSTRACT PRESENTATION. Coronary risk estimation and other cardiovascular comorbidities in moderate to severe psoriasis patients in Spain. RECOR study <i>Presenter: Carmen Garcia-Calvo</i>		
15.30 – 16.00	Coffee/Posters/Exhibits		
16.00 – 16.30	Key note lecture: Inflammatory mediators in cardiovascular disease with relevance to psoriatic disease <i>Chairs: Peter van de Kerkhof, Oliver FitzGerald</i> <i>Speaker: James De Lemos</i>		
16.45 – 17.45	INDUSTRY-SPONSORED SATELLITE SYMPOSIUM – Pfizer – Reducing the Burden of Psoriasis and Psoriatic Arthritis: A Framework for Action		
19.00	Welcome reception at the Stockholm City Hall By invitation of the City of Stockholm and the Stockholm City Council		

Photo: Moa Karlberg

Scientific Program

Time	GENERAL PROGRAM	Time	Complementary program
------	-----------------	------	-----------------------

Friday June 29

- 07.15 – 08.15** **Interesting psoriasis & psoriatic arthritis clinical cases**
Chair: Alan Menter
Three interesting cases from around the world with active audience participation
Panel chair: Dafna Gladman
Panelists/presenters: Vermén Verallo-Rowell, André Carvalho, Philip Mease
- 07.30 – 08.30** Posters/Exhibits
- 08.30 – 10.00** **Plenary 4: Psoriatic disease genetics**
Chairs: Alan Menter, Philip Mease
- 08.30 – 08.50 The genetics of psoriasis: old risks, novel loci
Speaker: Anne Bowcock
- 08.50 – 09.10 Are there genes that predispose psoriasis patients to psoriatic arthritis?
Speaker: Proton Rahman
- 09.10 – 09.25 Are skin and joints related?
 – Five key arguments pro
Speaker: Dafna Gladman
- 09.25 – 09.40 – Five key arguments against
Speaker: Jonathan Barker
- 09.40 – 10.00 Panel discussion
- 10.00 – 10.30** **Coffee/Posters/Exhibits**
- 10.30 – 12.00** **Plenary 5: Screening tools and outcome measures to assess psoriatic disease**
Chairs: Amit Garg, William Taylor
- 10.30 – 10.50 Outcomes measures for psoriatic disease
Speaker: Alan Menter
- 10.50 – 11.10 Screening tools for psoriatic arthritis: The role of the dermatologist in early diagnosis
Speaker: Abrar Qureshi
- 11.10 – 11.30 Composite indices and integrated assessment across the psoriatic spectrum
Philip Helliwell
- 11.30 – 11.50 Imaging for the diagnosis of psoriatic arthritis: Which and when?
Dennis McGonagle
- 11.50 – 12.00 **ABSTRACT PRESENTATION.** High prevalence of articular involvement in patients with severe psoriasis with poor performance of screening questionnaire
Presenter: Muhammad Haroon

Complementary program

Chairs: Joachim Barth, Hoseah Waweru

Please note that the Complementary program's sessions will be in hall C1-C3 located on level 2.

- | 10.00 | Complementary program opens for the day |
|---------------|--|
| 10.00 – 10.20 | Local treatment – still basic treatment
<i>Speakers: Gail Todd & Judy Wallace</i> |
| 10.20 – 10.40 | Treatment of “difficult to treat” areas
<i>Speaker: Birgitta Wilson Claréus</i> |
| 10.40 – 11.00 | Phototherapy – new aspects of an old method
<i>Speaker: Joachim Barth</i> |
| 11.00 – 11.20 | Conventional systemic treatment in psoriasis and psoriatic arthritis
<i>Speaker: Hoseah Waweru</i> |

Scientific Program

Time	GENERAL PROGRAM	Time	Complementary program
12.00 – 13.30	Lunch/Posters/Exhibits		
12.15 – 13.15	INDUSTRY-SPONSORED LUNCH SEMINAR – Janssen – Asking questions of biologic therapies: a joint approach		
13.30 – 15.30	Plenary 6: Psoriatic disease through the life cycle <i>Chairs: Edgardo Chouela, Neil McHugh</i>		
13.30 – 13.50	Depression, anxiety and coping: Is the impairment from psoriasis cumulative over a patient's lifetime? <i>Speaker: Alexa Kimball</i>		
13.50 – 14.10	Therapeutic challenges for females of child-bearing age <i>Speaker: Alan Menter</i>		
14.10 – 14.30	Psoriasis in childhood and adolescence: clinical characteristics and treatment perspectives <i>Speaker: Ricardo Romiti</i>		
14.30 – 14.50	Late onset psoriatic arthritis: is it different? <i>Speaker: Ignazio Olivieri</i>		
14.50 – 15.10	What do we know about the natural history of psoriasis? <i>Speaker: Mona Ståhle</i>		
15.10 – 15.20	ABSTRACT PRESENTATION. Different genetic background separates prepubertal and postpubertal onset of psoriasis <i>Presenter: Josefin Lysell</i>		
15.20 – 15.30	ABSTRACT PRESENTATION. Prevalence of overweight/obesity in psoriasis population and its therapeutic consequences in clinical setting. Experience from Biobadaderm <i>Presenter: Jose-Manuel Carrascosa</i>		
15.30 – 16.00	Coffee/Posters/Exhibits		
16.00 – 16.30	Key note lecture: Inflammatory bowel disease and psoriasis: common genetic and pathogenetic pathways? <i>Chairs: Ricardo Romiti, Ignazio Olivieri</i> <i>Speaker: Yehuda Chowers</i>		
16.45 – 17.45	INDUSTRY-SPONSORED SATELLITE SYMPOSIUM – Abbott International – Let's talk psoriasis! Psoriasis as a multifaceted, systemic, inflammatory disease: Are patients and physicians talking the same language?		
18.00 – 18.45	INDUSTRY-SPONSORED SATELLITE SYMPOSIUM – Novartis – IL-17A: Leading Pathway to Psoriasis and Therapeutic Innovation		
19.30	Conference dinner at the Vasa Museum		
			<p>Complementary program</p> <p><i>Chairs: Joachim Barth, Hoseah Waweru</i></p> <p>Please note that the Complementary program's sessions will be in hall C1-C3 located on level 2.</p> <hr/> <p>11.20 – 11.40 Biologics – a breakthrough in psoriasis treatment? <i>Speaker: Jonathan Barker</i></p> <p>11.40 – 12.00 Panel discussion</p> <p>Conference dinner at the restaurant in the Vasa Museum, where you can see the Royal Warship Vasa that came to such a dramatic end in Stockholm on August 10th 1628.</p>



Photo: Mikael Strimhed

Scientific Program

Time	GENERAL PROGRAM	Time	Complementary program
------	-----------------	------	-----------------------

Saturday June 30

- 07.15 – 08.15** **INDUSTRY-SPONSORED BREAKFAST SEMINAR – Eli Lilly** (Note: hall C1–C3)
– IL-17 and Psoriasis
- 07.30 – 08.30** Posters/Exhibits
- 08.30 – 09.30** **Plenary 7: Psoriatic disease – pathogenic insights**
Chairs: Vermén Verallo-Rowell, Christopher Ritchlin
- 08.30 – 08.50 The inflammasome and the alarmins: what starts psoriatic inflammation?
Speaker: Jürgen Schaubert
- 08.50 – 09.10 Synovitis in psoriatic arthritis: what can immunohistochemistry tell us?
Arno van Kuijk
- 09.10 – 09.30 What do T cells see in psoriasis lesions?
Speaker: Jörg Prinz
- 09.30 – 10.00** **Key note lecture: Comparative Effectiveness Analysis and Pharmacoeconomic modelling of biologics in Psoriasis**
Chairs: Vermén Verallo-Rowell, Christopher Ritchlin
Speaker: Aslam Anis
- 10.00 – 10.30** **Coffee/Posters/Exhibits**
- 10.30 – 12.00** **Plenary 8: Systemic therapies in psoriatic disease**
Chairs: Gail Todd, Arthur Kavanaugh
- 10.30 – 10.50 Methotrexate usage globally for psoriatic disease
Speaker: Menno De Rie
- 10.50 – 11.10 Do traditional DMARDs work in psoriatic arthritis?
Speaker: Neil McHugh
- 11.10 – 11.30 TNF antagonists in psoriatic arthritis
Speaker: Philip Mease
- 11.30 – 11.50 TNF α antagonists and p40 antibodies in psoriasis: similarities and differences
Speaker: Caitriona Ryan
- 11.50 – 12.00 **ABSTRACT PRESENTATION.** Secukinumab, a fully human anti-interleukin-17A antibody, improves signs and symptoms of psoriatic arthritis: A 24-week, double-blind, placebo-controlled, multicenter trial
Presenter: I McInnes

Complementary program

Chairs: Joachim Barth, Hoseah Waweru

Please note that the Complementary program's sessions will be in hall C1-C3 located on level 2.

10.00	Complementary program opens for the day
10.00 – 10.20	Psoriasis and psoriatic arthritis in childhood <i>Speaker: Josefin Lysell</i>
10.20 – 11.00	Impact of psoriasis on daily life activities <i>Speaker: Jörg Prinz</i>
11.00 – 11.20	Diet in psoriasis and psoriatic arthritis <i>Speaker: Anja Näslund</i>
11.20 – 11.40	Dermatologic nursing in psoriasis <i>Speaker: Barbara Page</i>
11.40 – 12.00	Panel discussion
12.00 – 12.10	Closing remarks

Scientific Program

Time	GENERAL PROGRAM	Time	Complementary program
12.00 – 13.30	Lunch/Posters/Exhibits		
12.15 – 13.15	INDUSTRY-SPONSORED LUNCH SEMINAR – LEO Pharma – Beyond the symptoms: Understanding and overcoming the real impact of psoriasis on patients		
13.30 – 15.00	Plenary 9: Psoriasis and psoriatic arthritis: disease activity and therapeutic challenges <i>Chairs: Mark Lebwohl, Ennio Lubrano</i>		
13.30 – 13.50	Evaluation and treatment of psoriatic nail disease <i>Speaker: Phoebe Rich</i>		
13.50 – 14.10	Minimal disease activity in psoriatic arthritis: indicator of remission or potential progression? <i>Speaker: Kurt de Vlam</i>		
14.10 – 14.30	Treatment algorithms and quality guidelines <i>Speaker: Arthur Kavanaugh</i>		
14.30 – 14.50	Body weight and treatment response <i>Speaker: Lluís Puig Sanz</i>		
14.50 – 15.00	ABSTRACT PRESENTATION. Predictive biomarkers for high responsiveness to treatment, and biomarkers associated with clinical response to treatment, in psoriasis patients treated with the anti-IL-17A monoclonal antibody, ixekizumab <i>Presenter: Robert Hoffman</i>		
15.00 – 15.30	Coffee/Posters/Exhibits		
15.30 – 16.50	Plenary 10: Concluding lectures <i>Chairs: Mona Stähle, Björn Guðbjörnsson</i>		
15.30 – 15.50	Psoriatic disease care: a team approach <i>Speaker: Alice B. Gottlieb</i>		
15.50 – 16.10	Systemic therapy: does it affect cardiovascular risk? <i>Speaker: Wolf-Henning Boehncke</i>		
16.10 – 16.30	Psoriasis and the burden of disease: calling for worldwide action <i>Speaker: Gerald G. Krueger</i>		
16.30 – 16.50	IFPA's work for worldwide recognition of psoriasis as a serious noncommunicable disease <i>Speaker: Lars Ettarp</i>		
16.50 – 17.00	Closing of scientific program		

Sunday July 1

IFPA Member meeting (closed session)

World Psoriasis Day Supporters Training Meeting
(pre-registration only)



Go beyond the surface **at Booth 6**

For a deeper look at results on
and below the skin with HUMIRA¹

HUMIRA[®], Rx, F, (adalimumab) LB04AB04, SPC 2012-01-20.

Indications: psoriasis, psoriatic arthritis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, crohn's disease. HUMIRA is presented as solution for injection, pre-filled syringe/pen, 40 mg. For complete information regarding indications, contraindications, warnings and precautions, adverse reactions, price and dosing, see: www.fass.se

Abbott Scandinavia AB, Box 1498, 171 29 Solna, Sweden.
Telephone +46 8 546 567 00. www.abbott.se

SWE/157/02Apr2012

**Please see Booth Representative for Indications,
Important Treatment Considerations, and SPC.**

HUMIRA
adalimumab
THINK DEEP. STRIKE DEEP.

Reference: 1. HUMIRA [Summary of Product Characteristics]. Berkshire, UK: Abbott Laboratories Ltd.

©2012 Abbott Laboratories Abbott Park, IL 60064 AI 822303 March 2012

 **Abbott**
A Promise for Life

Social Program



Photo: Mica Karlberg, Mikael Strömberg, Stockholm Waterfront Congress Centre, (The Vasa) Stefan Evensen, SMM (Statens maritima museer)

All social events are available for delegates and accompanying persons if pre-booked in the registration form. For late bookings please contact the registration desk to inquire about availability.

Wednesday, 27 June at 18.00

Conference Reception

The conference reception will take place at the conference venue on level 5, where light refreshments will be served

Location: Waterfront Congress Centre, level 5

Time: 18.00 – 19.00

Welcome Program

The welcome program features a short welcome from the President of the conference, Dr Alan Menter, and from the President of IFPA, Lars Ettarp, followed by an introduction to IFPA by Kathleen Gallant, Secretary of IFPA and a special viewing of IFPA's international documentary film project.

Location: Waterfront Congress Centre, level 5, room A3/A4

Time: 19:00 – 20:00

Please note: Delegates and accompanying persons must be pre-registered for the above events.

Thursday, 28 June at 19.00

Reception hosted by the City of Stockholm and the County of Stockholm

The reception takes place at the City Hall of Stockholm, one of the best known buildings in Sweden. It holds the most exclusive ballroom in Stockholm, hosting the yearly Nobel Banquet. The City Hall is famous for its hospitality, its unique art treasures, magnificent banquettes and intriguing history - attracting close to 400,000 visitors each year. Light refreshments will be served.

Location: Stockholm City Hall

Time: 19.00 (sharp)

Please note: Delegates and accompanying persons must be pre-registered. The official invitation card from the City of Stockholm should be shown at the entrance. The ticket received together with the name badge should be exchanged for the official card (see ticket for further details).

Friday, 29 June at 19.30

Conference Dinner

Welcome to a truly unique conference dinner in the spectacular Vasa museum with the magnificent warship Vasa as your dining companion. The Vasa sunk on her first voyage in 1628, and has since her salvage in 1961 been one of the most beloved and awe-inspiring sights in Stockholm. The dinner, featuring local delicacies, will be followed by dance to live music in the Vasa Museum restaurant, which has a beautiful view over the Stockholm harbour inlet. There the bar will also be open to serve the guests refreshing beverages (not included in the dinner price).

Location: The Vasa Museum, Galärvarvsvägen 14, Djurgården, Stockholm

Time: 19.30 (sharp) – 00.30

Price: SEK 700 (excl. VAT)

Please note: Please bring your ticket received upon registration. The temperature in the banquet hall is kept at a steady 18° C for preservation purposes, so make sure to dress accordingly. You can read more about the museum at www.vasamuseet.se/en/.

How to get here:

WALK: From the Central Station. Approximate time: 30 minutes.

From Karlaplan station. Approximate time: 10 minutes.

TRAM: The easiest way to get to the Vasa Museum is by tram. From the city centre (by Sergels torg square, on Hamngatan street) take tram number 7 towards Waldemarsudde.

BUS: Bus 44 to bus stop Nordiska museet/Vasamuseet.

Bus 69 and 76 to bus stop Djurgårdsbron.

METRO: Red line to station Karlaplan. From there a 10 minute walk or bus 44 to bus stop Nordiska museet/Vasamuseet.

FERRY: Ferry from Slussen all year round and from Nybroplan during the summer.

Visit www.sl.se for timetables and other information about the tram, the buses and the metro.

Please visit
the Novartis
Exhibit #9



Novartis proudly supports the
3rd World Psoriasis & Psoriatic Arthritis Conference
in its efforts to assist patients and their families.



www.novartis.com

4/12 NVS-IFPA2012-f1

Lilly salutes the International Federation of Psoriasis Associations.

SELLY00026

Hotels and social event locations



Please Join Us for an Educational Symposium entitled,

IL-17A: Leading Pathway to Psoriasis and Therapeutic Innovation



CHAIRMAN

Carle Paul, MD, PhD
 Department of Dermatology,
 Paul Sabatier University and
 Toulouse University Hospital,
 Toulouse, France

AGENDA

- > New insights on the pathophysiology of psoriasis
- > New biologic agents targeting the IL-17 pathway

Friday, 29 June 2012 | 18:00-18:45

Stockholm Waterfront Congress Centre
 Nils Ericsson Plan 4
 A1 Plenary Hall

The dawn of change in psoriatic disease treatment



Discover how patients and doctors can partner to improve care in psoriatic disease

Thursday, 28 June 2012, 12.15–13.15

Main Auditorium, Stockholm Waterfront Congress Centre

Peter van de Kerkhof

Radboud University
Nijmegen, The Netherlands

Ottfrid Hillmann

President
EUROPSO

Carle Paul

Paul Sabatier University
Toulouse, France

Kim Papp

Probit Medical Research
Waterloo, ON, Canada

With inputs from patients and clinical experts, this forum will explore ways to build partnerships for a common commitment to psoriatic disease treatment.

Seminar arranged and sponsored by Celgene International

Copyright © 2012, Celgene International. MED/PSD/APRI/2012-04/01

LEO Pharma invites you to
LEO Symposium Saturday, 30th June,
12:15 - 13:15

**Beyond the symptoms:
Understanding and overcoming the real
impact of psoriasis on patients.**

Visit the LEO booth #1 for more information


Look forward to seeing you!



Helping *people* living with psoriasis.



Stockholm Waterfront Congress Centre



- A1 – Auditorium
- C1 – C3 Complementary program
- 21 – Press room
- 22 – Staff room

- 23 – IFPA Meeting room
- 24 – IFPA Meeting room
- 37 – Speakers’ preview room
- Balcony – Poster exhibition

Exhibition

- | | | |
|------------------------|------------------------------------|--|
| 1. LEO Pharma | 12. GlobalMed Technologies | 21. Information booth |
| 2. Pfizer | 13. Kernel Medical Equipment | 22. The Swedish Psoriasis Association |
| 3. Pfizer | 14. Celgene | 23. ISNG |
| 4. Coffee area | 15. Celgene | 24. IPC |
| 5. IFPA | 16. Satellite Symposia information | 25. BADV |
| 6. Abbott | 17. Upcoming events | 26. PsoAfrica |
| 7. Janssen | 18. H. Waldmann | 27. PsoAsia |
| 8. Janssen | 19. Quantel Derma | 28. LATINAPSO |
| 9. Novartis | 20. Spa Smrdáky | 29. EUROPISO |
| 10. Novartis | | Central booth – IFPA Under the Spotlight |
| 11. Lüllau Engineering | | |



Thursday, 28 June 2012

16:45 – 17:45

Auditorium A1

Waterfront Congress Centre

Stockholm, Sweden

Reducing the

Burden of Psoriasis and Psoriatic Arthritis:

A Framework for Action



Faculty

Professor Mona Ståhle

*Karolinska University Hospital
Karolinska Institutet
Stockholm, Sweden*

Professor Jonathan Barker

*St John's Institute of Dermatology (King's College London)
London, England*

Dr Philip Mease

*Swedish Medical Center
University of Washington School of Medicine
Seattle Rheumatology Associates
Seattle, Washington USA*

General information

Abstract book

Accepted abstracts are published in the conference abstract book, which is distributed to all delegates in the conference bag.

Badges

The participant name badge will be provided at the registration desk. All participants are requested to wear the badge throughout the conference. Only badge holders will be admitted to the sessions.

Business centre

A business centre is available within the venue located on level 3 and will be open during the conference hours.

Certificate of attendance

You will find a certificate of attendance in the conference bag.

CME Credits

A Certificate of attendance will be available for all participants attending the conference. For full participation 18 EACCME credit hours will be awarded.

EACCME credits are recognized by the American Medical Association (AMA) towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, please contact the AMA.

In order to collect your CME certificate, please complete the survey included in the conference bag. Return the completed survey to the registration desk, with start from Friday 29 June at 14.00, in return for the CME certificate.

Cloakroom

The cloakroom is located on the same level as the main entrance (level 4). The cloakroom is open during the conference hours. The cost for using the cloakroom is SEK 20 per item and cash or credit card payment is possible.

Conference organizer

All matters regarding registration, hotel booking, social events, abstract handling, exhibition management and general information are managed by Congrex Sweden AB. Congrex Sweden AB has been appointed official conference organizer for this event. The Congrex Group works internationally with offices in Sweden, The Netherlands, United Kingdom and Latin America, offering integrated solutions for the association services industry and corporate and governmental meetings. For more information, please visit: www.congrex.com

Disclaimer/Liability

The conference organizers cannot accept liability for injuries or losses of whatever nature incurred by participants and/or accompanying persons, nor for loss of or damage to their luggage and/or personal belongings. Please check the validity of your own travel insurance. All reasonable endeavours will be made to hold the 3rd World Psoriasis & Psoriatic Arthritis Conference 2012 and to present its program as scheduled under circumstances which assure the comfort and safety of all participants and accompanying persons. However, neither the IFPA nor its committees, representatives or agents, shall be held liable by any person as a result of the cancel-

lation of the conference or of any of the arrangements, programs or plans connected therewith, or for any injury, damage or inconvenience which may be suffered by any person while travelling to or from, or during such person's presence in Sweden in connection with this conference. Participants and accompanying persons are advised to purchase their own insurance against any such occurrences.

Emergency phone numbers

Police	112
Ambulance	112
Fire brigade	112

Exhibition

See page 17 for further details.

Evaluation

After the conference you will receive an evaluation form by e-mail. Your opinion is very important for us and we appreciate that you take your time to fill it out.

Hearing aid

A limited number of receivers for hearing aid are available in the main hall only – A1.

Please contact the hall hostess for assistance with the receiver.

Internet

Wireless internet will be available within the conference venue. The password is psoriasis.

Language

The official conference language is English. No simultaneous interpretation will be made.

Lost and found

Contact the registration desk in case of personal belongings being lost or found. Belongings not picked up during the conference will be handed over to Waterfront.

Meals


Morning and afternoon coffee will be served in the exhibition area and on level 2. Lunches are not included in the registration fee. However, there are several restaurants in the vicinity of the conference venue.

Smoking policy

This is a non-smoking conference. Sweden has a non-smoking policy, i.e. smoking is prohibited in public buildings, public transport, taxis, buses and trains.

Speakers' preview room

Speakers are requested to use the facility to ensure that their presentation projects clearly and is in the correct order. Presentations that haven't been admitted previously, should be handed over to the technical staff a minimum of 2 hours before the session starts. Presentations received after this deadline cannot be guaranteed optimal audio-visual support. The speakers' preview room will be in Room 37.



PUT PSORIASIS ON THE AGENDA NOW!

JOIN IFPA'S CAMPAIGN BY HAVING YOUR PICTURE TAKEN IN THE IFPA BOOTH AND GET A FREE WORLD PSORIASIS DAY PIN.



World Psoriasis Day is presented by the International Federation of Psoriasis Associations, IFPA

$$\begin{array}{r} 365 \\ -4^* \\ \hline 361 \end{array}$$

That's **361** days to
focus on life... not psoriasis

Be inspired and see how together we can make a difference to psoriasis patients - visit the Stelara® stand at WPPAC 2012.

Stelara® is indicated for the treatment of moderate-to-severe plaque psoriasis¹.



Stelara®
(ustekinumab)

STELARA® 45 mg solution for injection in pre-filled syringe

PRESCRIBING INFORMATION: ACTIVE INGREDIENT(S): Ustekinumab. Please refer to Summary of Product Characteristics (SmPC) before prescribing. **INDICATION(S):** Treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA. **DOSAGE & ADMINISTRATION:** Under the guidance and supervision of a physician experienced in diagnosis and treatment of psoriasis. Subcutaneous injection. Avoid areas with psoriasis. For self-injecting patients ensure appropriate training, follow-up and monitoring during treatment. **Adults & Elderly:** Patients ≤ 100kg, 45 mg at week 0 followed by a 45 mg dose at week 4, then every 12 weeks. Patients >100 kg, 90 mg at week 0 followed by a 90 mg dose at week 4, then every 12 weeks (45 mg was less effective in these patients). Consider discontinuation if no response after 28 weeks. **Children <18 years:** Not recommended. **Renal & Hepatic impairment:** Not studied. **CONTRAINDICATIONS:** Hypersensitivity to product; clinically important, active infection. **SPECIAL WARNINGS & PRECAUTIONS: Infections:** Potential to increase risk of infections and reactivate latent infections. Caution in patients with a chronic infection or history of recurrent infection, particularly TB. Patients should be evaluated for tuberculosis prior to initiation of STELARA. Consider anti-tuberculosis therapy prior to initiation of STELARA in patients with past history of latent or active tuberculosis. Patients should seek medical advice if signs or symptoms suggestive of an infection occur. If a serious infection develops, they should be closely monitored and STELARA should not be administered until infection resolves. **Malignancies:** Potential to increase the risk of malignancy. No studies in patients with a history of malignancy or in patients who develop malignancy while receiving STELARA. **Concomitant immunosuppressive therapy:** Caution, including when changing immunosuppressive biologic agents. **Hypersensitivity reactions:** Serious hypersensitivity reactions (anaphylaxis and angioedema) reported, in some cases several days after treatment. If these occur, discontinue STELARA immediately and institute appropriate therapy. **Immunotherapy:** Not known whether STELARA affects allergy immunotherapy. **Latex sensitivity:** Needle cover contains natural rubber (latex), may cause allergic reactions. **SIDE EFFECTS: Serious side effects:** Serious infections, malignancies. **Very common:** upper respiratory tract infection, nasopharyngitis. **Common:** hypersensitivity reactions (rash, urticaria), cellulitis, viral upper respiratory tract infection, depression, dizziness, headache, pharyngolaryngeal pain, nasal congestion, diarrhoea, pruritus, back pain, myalgia, arthralgia, fatigue, injection site erythema, antibodies to ustekinumab. **Uncommon:** herpes zoster infection, injection site reactions. **Rare:** serious hypersensitivity reactions (including anaphylaxis, angioedema), facial palsy. **Refer to SmPC for other side effects. FERTILITY:** The effect of ustekinumab has not been evaluated. **PREGNANCY:** Should be avoided. Women of childbearing potential: Use effective contraception during treatment and

for at least 15 weeks post-treatment. **LACTATION:** Limited data in humans. **INTERACTIONS:** *In vitro*, STELARA had no effect on CYP450 activities. **Vaccinations:** Live vaccines should not be given concurrently with STELARA, and should be withheld for at least 15 weeks after last dose of STELARA. STELARA can resume at least 2 weeks after such vaccinations. No data on secondary transmission of infection by live vaccines in patients receiving STELARA. **Concomitant immunosuppressive therapy:** The safety and efficacy of STELARA in combination with other immunosuppressants, including biologics, or phototherapy have not been evaluated. **LEGAL CATEGORY:** POM **PRESENTATIONS, PACK SIZES, & PRODUCT LICENCE NUMBERS:** STELARA 45mg: 1 x 0.5ml pre-filled syringe. EU/1/08/494/003. **MARKETING AUTHORISATION HOLDER:** JANSSEN-CILAG INTERNATIONAL NV, Turnhoutseweg 30, B-2340 Beerse, Belgium. **FURTHER INFORMATION IS AVAILABLE FROM:** Janssen-Cilag Ltd, 50 – 100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG UK. © Janssen-Cilag Ltd 2012. Prescribing information last revised: 20/03/2012 PIVER: 20032012

Adverse events should be reported to local Janssen company.

1. Stelara® European Summary of Product Characteristics. Date: March 2012.
*4 = maintenance therapy after 2 induction doses.

Products mentioned in this document may not be registered in all countries. Prescribing information may vary per country. Health Care Providers must refer to their country prescribing information.

Janssen Pharmaceutica N.V. Stelara® (ustekinumab)

Injektionsvätska, lösning i förfylld spruta i doserna: 45 mg/0,5 ml och 90 mg/0,5 ml L04AC05. Receptbelagt. F. Indikation: Stelara är indicerat för behandling av måttligt till svår plackpsoriasis hos vuxna som inte svarat på andra systemiska behandlingar såsom ciklosporin, metotrexat och PUVA, eller när intolerans eller kontraindikationer föreligger mot sådana behandlingar. Trafikvarning: Inga studier har utförts. Datum för senaste översyn av SPC 2012-02-21.

För fullständig produktinformation och aktuellt pris, se www.fass.se
Janssen-Cilag AB, P.O. box 7073, SE-192 07 Sollentuna, Sweden, phone +46 8 626 50 00
Date of preparation: April 2012 STE pso ADS MAR2012 EMEA 209

Stockholm and Sweden




Photo: Jeppe Wikström/Stockholm Visitors Board (Drottningholm Palace, UNESCO World Heritage), Ola Ericson/imagebank.sweden.se (Midsummer dance), Nicho Södling/Stockholm Visitors Board (Old Town, Stockholm), Helena Wahlman/imagebank.sweden.se (Kayaking in the Stockholm Archipelago), Ola Ericson/imagebank.sweden.se (Ericsson Globe, the largest spherical structure in the world), Jeppe Wikström/Stockholm Visitors Board (Swimming in Stockholm), Ola Ericson/imagebank.sweden.se (The Royal Palace, Stockholm)

Arlanda Airport

Arlanda Airport is located 49 km North of Stockholm. The Arlanda Express is the train service that links Stockholm City with the Airport. The journey normally takes 20 minutes from the Central Station.

Taxi: We recommend that you request a fixed price from the city to the airport, approx. SEK 550.

Bus: There is a direct bus connection from the City Terminal/Central station to Arlanda Airport. The journey takes about 40 minutes and costs SEK 100. The bus leaves every 10 minutes.

Business hours & shopping

Shops are open between 10.00 and 18.00 hrs on weekdays and from 10.00 to 15.00 on Saturdays. Shops in the city centre have extended opening hours, some even on Sundays between 12.00 and 16.00 hrs.

Climate and clothing

The average temperature in June is around 18 C (64 F).

Credit cards

International credit cards are accepted for payments in hotels, restaurants and shops.

Currency

The currency in Sweden is the Swedish krona, SEK.

Time zone

Sweden is in the Central European Time zone.

Tourist information

A representative from the Stockholm Visitors Board will be present in the information desk from 12.00 to 17.00 during the conference where you will be able to book sightseeing tours, purchase Stockholm cards and transportation cards. For more extensive tourist information about Stockholm please visit the website: www.visitstockholm.com/en/. You will find more practical information and tips about Sweden on www.visitsweden.com.

Transportation

The city centre of Stockholm is easily accessible by foot, and the transportation network with buses, trams and underground is extensive. For more information about public transportation, visit www.sl.se. If you instead choose to travel by taxi, make sure that it is an approved taxi with metered fare. These taxis always have yellow license plates. Credit cards are readily accepted and often preferred to cash.

Abstract Titles

Psoriasis and Psoriatic Arthritis relationship

P002 Early treatment of psoriatic arthritis is associated with improved outcomes: findings from the etanercept PRESTA trial

Kirkham, Bruce¹; Li, Wenzhi²; Boggs, Robert²; Nab, Henk³; Tarallo, Miriam³

¹Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; ²Pfizer Inc., Collegeville, PA, United States; ³Pfizer Europe, Rome, Italy

P003 Bone alterations in psoriatic patients – an early sign of psoriatic arthritis?

Finzel, Stephanie¹; Renner, Regina²; Englbrecht, Matthias¹; Schett, Georg¹; Rech, Jürgen¹; Sticherling, Michael²

¹Department of Internal Medicine 3, Rheumatology and Immunology, University Hospitals Erlangen, Erlangen, Germany; ²Department of Dermatology, University Hospitals Erlangen, Erlangen, Germany

P004 Effects of PUVA and narrowband UVB on adenosine deaminase activities in plasma and tissue samples of patients with psoriasis

Ozyurt, Kemal¹; Ozturk, Perihan¹; Yıldız, Sinem²; Uksal, Umit³

¹KSU Medicine Faculty, Dermatology, Kahramanmaraş, Turkey; ²Kayseri State Hospital, Dermatology, Kayseri, Turkey; ³Taksim Alman Hospital, Dermatology, Istanbul, Turkey

P005 Unilateral psoriasis: a case report

Yavuz, Cahit¹; Ataseven, Arzu¹; Ozturk, Perihan²

¹Department of Dermatology, Konya Education and Research Hospital, Konya, TURKEY, Konya, Turkey; ²Department of Dermatology, Kahramanmaraş Sutcuymam University, Kahramanmaraş, TURKEY, Kahramanmaraş, Turkey

P006 Two cases of concomitant vitiligo and psoriasis

Ataseven, Arzu¹; Ozturk, Perihan²; Karaosmanoglu, Ilknur³

¹Department of Dermatology, Konya Education and Research Hospital, Konya, TURKEY, Konya, Turkey; ²Department of Dermatology, Kahramanmaraş Sutcuymam University, Kahramanmaraş, TURKEY, Kahramanmaraş, Turkey; ³Department of Pathology, Konya Education and Research Hospital, Konya, TURKEY, Konya, Turkey

P007 The prevalence of rheumatologist-diagnosed psoriatic arthritis in psoriasis patients in European/North American dermatology clinics: Results of the PREPARE study

Mease, Philip J.¹; Papp, Kim A.²; Gladman, Dafna³; Thaci, Diamant⁴; Northington, Robert⁵; Fuiman, Joanne⁵; Boggs, Robert⁵; Alvarez, Daniel⁶

¹Swedish Medical Center, University of Washington School of Medicine, Seattle, WA, United States; ²Probit Medical Research, Waterloo, Ontario, Canada; ³University of Toronto, Toronto, Ontario, Canada; ⁴J. W. Goethe University, Frankfurt, Germany; ⁵Pfizer Inc, Collegeville, PA, United States

P008 Epidemiology of psoriasis and psoriatic arthritis in Scotland

McHattie, Lorna W.¹; Diack, H. Lesley¹; Stewart, Derek¹; Ormerod, Anthony O.²; Burden, A. David³

¹Robert Gordon University, School of Pharmacy and Life Sciences, Aberdeen, United Kingdom; ²University of Aberdeen, Aberdeen, United Kingdom; ³Greater Glasgow and Clyde Health Board, Department of Dermatology, Glasgow, United Kingdom

P009 Comparison of composite disease activity scores in psoriatic arthritis

Helliwell, Philip¹; FitzGerald, Oliver²; Pedersen, Ronald³; Bananis, Eustratios³

¹Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom; ²St. Vincent's University Hospital, Dublin, Ireland; ³Pfizer Inc., Collegeville, PA, United States

P010 High prevalence of articular involvement in patients with severe psoriasis with poor performance of screening questionnaires

Haroon, Muhammad¹; Kirby, Brian²; FitzGerald, Oliver¹

¹St Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland; ²St Vincent's University Hospital, Department of Dermatology, Dublin, Ireland

P011 Prevalence of psoriatic arthritis in psoriatic patients attending dermatologists' units in Spain. PREVAL study

Zarco, Pedro¹; López-Esteban, Jose Luis²; Fernández-Sueiro, Jose Luis³; García-Calvo, Carmen⁴

¹Fundación Hospital Alcorcón, Department of Rheumatology, Alcorcón, Madrid, Spain; ²Fundación Hospital Alcorcón, Department of Dermatology, Alcorcón, Madrid, Spain; ³Hospital Universitario Juan Canalejo, Department of Rheumatology, A Coruña, Spain; ⁴Pfizer Spain, Medical Department, Madrid, Spain

Genetics

P012 Search and exploration candidate genes and their role in pathogenesis of psoriasis

Sobolev, Vladimir¹; Soboleva, Anna; Mezentsev, Alexandre; Bruskin, Sergey

Institute of General Genetics, Functional Genomics, Moscow, Russian Federation

P013 Risk variants for psoriasis in a large case-control collection and association with clinical subphenotypes

Julià, Antonio¹; Tortosa, Raül¹; Hernanz, José Manuel²; Cañete, Juan D.³; Fonseca, Eduardo⁴; Ferrándiz, Carlos⁵; Unamuno, Pablo⁶; Puig, Lluís⁷; Fernández-Sueiro, José Luis⁴; Sanmartí, Raimon³; Rodríguez, Jesús⁸; Gratacós, Jordi⁹; Dauden, Esteban¹⁰; Sánchez-Carazo, José Luis¹¹; López-Esteban, José Luis¹²; Moreno-Ramírez, David¹³; Queiro, Rubén¹⁴; Montilla, Carlos¹⁵; Torre-Alonso, Juan Carlos¹⁶; Pérez-Venegas, José Javier¹⁷; Vanaclocha, Francisco¹⁸; Herrera, Enrique¹⁹; Muñoz-Fernández, Santiago²⁰; González, Carlos²; Roig, Daniel²¹; Erra, Alba²²; Acosta, Isabel¹; Fernández-Nebro, Antonio²³; Zarco, Pedro¹²; Alonso, Arnald¹; López-Lasanta, María¹; García-Montero, Andrés²⁴; Gelpi, Josep Lluís²⁵; Absher, Devin²⁶; Marsal, Sara¹

¹Vall d'Hebron Hospital Research Institute, Barcelona, Spain; ²Hospital Universitario Gregorio Marañón, Madrid, Spain; ³Hospital Clínic de Barcelona, Barcelona, Spain; ⁴Complejo Hospitalario Juan Canalejo, A Coruña, Spain; ⁵Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; ⁶Hospital Universitario de Salamanca, Salamanca, Spain; ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; ⁸Hospital Universitario de Bellvitge, Barcelona, Spain; ⁹Hospital Parc Taulí, Sabadell, Spain; ¹⁰Hospital Universitario La Princesa, Madrid, Spain; ¹¹Hospital General Universitario de Valencia, Valencia, Spain; ¹²Hospital Universitario Fundación Alcorcón, Madrid, Spain; ¹³Hospital Universitario Virgen Macarena, Sevilla, Spain; ¹⁴Hospital Universitario Central de Asturias, Oviedo, Spain; ¹⁵Hospital Virgen de la Vega, Salamanca, Spain; ¹⁶Hospital Monte Naranco, Oviedo, Spain; ¹⁷Hospital de Jerez de la Frontera, Cádiz, Spain; ¹⁸Hospital Universitario 12 de Octubre, Madrid, Spain; ¹⁹Hospital Universitario Virgen de la Victoria, Málaga, Spain; ²⁰Hospital Universitario Infanta Sofía, Madrid, Spain; ²¹Centre d'Atenció Especialitzada de Cornellà, Barcelona, Spain; ²²Hospital Sant Rafael, Barcelona, Spain; ²³Hospital Regional Universitario Carlos Haya, Málaga, Spain; ²⁴Universidad de Salamanca, Salamanca, Spain; ²⁵Barcelona Supercom-

puting Centre, Barcelona, Spain; ²⁶HudsonAlpha Institute for Biotechnology, Huntsville, United States

P014 Influence of VEGF gene polymorphisms on clinical features of psoriatic arthritis and SAPHO syndrome

Przepiera-Bedzak, Hanna¹; Ciechanowicz, Andrzej²; Brzosko, Iwona¹; Brzosko, Marek¹

¹Pomeranian Medical University in Szczecin, Department of Rheumatology and Internal Diseases, Szczecin, Poland; ²Pomeranian Medical University in Szczecin, Department of Laboratory Diagnostics and Molecular Medicine, Szczecin, Poland

P015 Association of HLA class I and II alleles with psoriasis in Pakistani population

Munir, Saeeda¹; Rahman, Simeen Ber²; Saba, Nusrat¹; Mazhar, Kehkashan¹; Ahmad, Wasim³; Rehman, sadia¹

¹Institute of Biomedical & Genetic Engineering, Islamabad, Pakistan; ²Simeen's Skin & Laser Centre, Peshawar Road, Rawalpindi, Pakistan; ³Quaid-i-Azam University, Islamabad, Pakistan

P016 Different genetic background separates prepubertal and postpubertal onset of psoriasis

Lysell, Josefin¹; Padyukov, Leonid²; Kockum, Ingrid³; Nikamo, Pernilla⁴; Ståhle, Mona¹

¹Department of Medicine, Unit of Dermatology and Venereology, Stockholm, Sweden; ²Department of Medicine, Unit of Rheumatology, Stockholm, Sweden; ³Department of Clinical neuroscience, Stockholm, Sweden; ⁴Institution of Medicine, Unit of Dermatology and Venereology, Stockholm, Sweden

P017 A qualitative analysis of digitopalmar dermatoglyphics in 400 psoriasis and psoriatic arthritis patients from Croatia

Jajica, Zrinka

University Department of Physical Medicine, Sestre Milosrdnice University Hospital, Zagreb, Croatia

P018 Time to event and progressive multi-state analyses confirm the association between human leukocyte antigen alleles and the development of arthritis mutilans in patients with psoriatic arthritis

Chandran, Vinod¹; Cook, Richard²; Thavaneswaran, Arane¹; Lee, Ker-Ai²; Fawnda, Pellett¹; Gladman, Dafna¹

¹Toronto Western Hospital, Division of Rheumatology, Toronto, Canada; ²University of Waterloo, Department of Statistics and Actuarial Science, Waterloo, Canada

Pathophysiology and immunobiology

P019 Anti-inflammatory potential of bacterial components

Zakostelska, Zuzana¹; Kverka, Miloslav¹; Klimesova, Klara¹; Rossmann, Pavel¹; van der Zee, Ruurd²; van Eden, Willem²; Tlaskalova-Hogenova, Helena¹

¹Institute of Microbiology AS CR, Department of Immunology and Gnotobiology, Prague, Czech Republic; ²Utrecht University, Faculty of Veterinary Medicine, Department of Infectious diseases and Immunology, Utrecht, Netherlands

P020 The role of human microRNA-31 in psoriasis

Xu, Ning; Meisgen, Florian; Ståhle, Mona; Sonkoly, Enikő; Pivarcsi, Andor

Karolinska Institutet, Unit of Dermatology, Department of Medicine, Stockholm, Sweden

P021 Langerhans cells in psoriasis

Wikén, Maria; Cheuk, Stanley; Bergh, Kerstin; Ståhle, Mona; Eidsmo, Liv

Karolinska Institutet, Medicine, Stockholm, Sweden

P022 Obesity and psoriasis - Vaspin as a possible link?

Vester, Katharina¹; Saalbach, Anja¹; Tremel, Jenny¹; Anderegg, Ulf¹; Averbek, Marco¹; Bodendorf, Marc¹; Ziemer, Mirjana¹; Beck-Sickinger, Annette G.²; Bluher, Matthias³; Simon, Jan C.¹

¹University of Leipzig, Department of Dermatology, Venerology and Allergy, Leipzig, Germany; ²University of Leipzig, Institute of Biochemistry, Faculty of Life Sciences, Pharmacy; LIFE –Leipzig Research Center for Civilization Diseases, Leipzig, Germany; ³University of Leipzig, Department of Medicine, Medical Faculty; LIFE –Leipzig Research Center for Civilization Diseases, Leipzig, Germany

P023 Anti-TNF- α therapy alters serum miRNA expression profiles in psoriasis patients

Pivarcsi, Andor; Meisgen, Florian; Xu, Ning; Ståhle, Mona; Sonkoly, Enikő

Karolinska Institutet, Dept of Medicine, Dermatology and Venereology Unit, Stockholm, Sweden

P024 Skin equivalent as an experimental model to study psoriasis

Soboleva, Anna; Mezentssev, Alexandre; Sobolev, Vladimir; Bruskin, Sergey
Vavilov Institute of General Genetics, Functional Genomics, Moscow, Russian Federation

P025 Small intestine microflora at psoriasis. Its possible role in pathogenesis.

Peslyak, Mikhail¹; Gumayunova, Natalia²; Nesterov, Alex²; Potaturkina-Nesterova, Natalia²

¹Kudits, Moscow, Russian Federation; ²Ulyanovsk State University, Ulyanovsk, Russian Federation

P026 Differential scanning calorimetry analysis of human plasma in different psoriasis stages

Moizzi, Mehdi¹; Fekecs, Tamas²; Zapf, István³; Ferencz, Andrea⁴; Lorinczy, Denes⁵

¹Medical University of Pécs, Dermatology, Pécs, Hungary; ²University of Pécs, Medical School, Dermatology, Pécs, Hungary; ³University of Pécs, Medical School, Surgery, Pécs, Hungary; ⁴Semmelweis University, Medical School, Surgery, Budapest, Hungary; ⁵University of Pécs, Medical School, Biophysics, Pécs, Hungary

P027 The role of miR-146a in innate immunity of keratinocytes

Meisgen, Florian; Xu, Ning; Ståhle, Mona; Sonkoly, Enikő; Pivarcsi, Andor

Karolinska Institutet, Dept of Medicine Solna, Stockholm, Sweden

P028 Fc gamma receptors in active psoriatic arthritis


Matt, Johann Peter¹; Lindqvist, Ulla Ruth Kristina¹; Kleinau, Sandra²

¹Department of medical sciences, Rheumatology, Uppsala university, Uppsala, Sweden; ²Dept. of Cell and Molecular Biology, Biomedical Center, Uppsala University, Uppsala, Sweden

P029 Evaluation of cardio-protective role of methotrexate in psoriasis

Malhotra, Suresh¹; Dhaliwal, Gurinder¹; Puri, Karanjit¹; Mahajan, Mridula²

¹Govt medical collage, Dermatology, Amritsar, India; ²Govt medical collage, Biochemistry, Amritsar, India



What you get

- **Current**
- **Clinical**
- **Definitive**

Where you get it **THE JOURNAL**

To subscribe: visit jrheum.org online or send in your completed coupon below

Rates for 2012 calendar year USA/INTERNATIONAL

	Print + Online	Online Only
INDIVIDUALS:	\$910 US	\$260 US
INSTITUTIONAL:		
- Multisite*	On request	On request
- Multiuser (IP ranges)	\$920 US	\$870 US
- Basic (up to 4 users)	\$495 US	\$445 US
TRAINEES*	\$175 US	\$125 US+
Airmail (ADD)	\$80 US	

*No change in my access requirements.

[] Please renew at current rate

For terms of access visit jrheum.org

*Supervisor certification required below.

NAME OF SUPERVISOR: _____

SUPERVISOR SIGNATURE: _____

SUPERVISOR TELEPHONE: _____

Mail completed form to: The Journal of Rheumatology

365 Bloor Street East, Suite 901
Toronto, Ontario Canada M4W 3L4
Phone: (416) 967-5155
Fax: (416) 967-7556
E-mail: subscriptions@jrheum.com

or

1051 Clinton Street
Buffalo, NY, 14206-2823 USA

Please enter my 2012 subscription to **The Journal of Rheumatology**

Name (please print) _____

Address _____

City _____ State/Province _____

Country _____ Zip/Postal Code _____

Contact E-mail _____

Amount Enclosed \$ _____ Bill Me _____

Telephone Number _____ Fax Number _____

VISA/MasterCard Number _____ Expiration Date _____

Signature _____ CVV _____

All subscriptions are for the calendar year. Renewals for print subscriptions received after May 31, 2012 will be charged an additional \$5 per back issue. Back issues: 3 years including current year are available if in stock. Single copies are available at \$30 each. Claims: US 2 months, elsewhere 4 months from issue date, e.g., March 1 and May 1, respectively, for the January issue. **PRIVACY POLICY:** For details of our privacy policy, visit our website at www.jrheum.org.

Abstract Titles continued

P030 Immune regulation at the border of psoriatic lesions

Keijzers, Romy¹; van Erp, Piet¹; de Boer-van Huizen, Roelie¹; Joosten, Irma²; Koenen, Hans²; van de Kerkhof, Peter¹

¹Radboud University Nijmegen Medical Centre, Department of Dermatology, Nijmegen, Netherlands; ²Radboud University Nijmegen Medical Centre, Laboratory of Medical Immunology, Nijmegen, Netherlands

P031 Comparison between involved and uninvolved psoriatic skin in a pathological skin model produced with the self-assembly approach

Jean, Jessica¹; Duque-Fernandez, Alexandra¹; Bernard, Geneviève¹; Soucy, Jacques²; Pouliot, Roxane¹

¹Faculté de Pharmacie, Université Laval, Québec, Canada, Centre LOEX de l'Université Laval, Génie tissulaire et régénération, Québec, Canada; ²Département de Dermatologie, Hôpital de l'Enfant-Jésus, Québec, Canada

P032 Clinical and immunological response to treatment of psoriasis in the blue lagoon compared with narrow-band UVB monotherapy

Eysteinsdottir, JH¹; Olafsson, JH¹; Davidsson, S²; Brynjólfsson, A⁴; Sigurgeirsson, B³; Ludvíksson, BR⁵

¹Sahlgrenska University Hospital, Department of Dermatology and Venereology, Gothenburg, Sweden; ²University Hospital of Iceland, Department of Dermatology and Venereology, Reykjavik, Iceland; ³University of Iceland, Faculty of Medicine, Reykjavik, Iceland; ⁴Blue Lagoon inc, Grindavik, Iceland; ⁵University Hospital of Iceland, Department of Immunology, Reykjavik, Iceland

P033 Systemically elevated Th1-, Th2- and Th17-associated chemokines in psoriasis

Ekman, Anna-Karin¹; Sigurdardottir, Gunnthorunn¹; Carlström, Maria¹; Kartul, Natalja¹; Jenmalm, Maria²; Enerbäck, Charlotta¹

¹Department of Clinical and Experimental medicine, Division of Cell biology and Dermatology, Linköping University, Linköping, Sweden; ²Department of Clinical and Experimental medicine, Division of Clinical immunology, Linköping University, Linköping, Sweden

P034 Characterization of skin resident T cells in psoriasis treated with UVB or anti-TNFalpha therapy

Cheuk, Stanley; Wikén, Maria; Ståhle, Mona; Eidsmo, Liv

Karolinska Institutet, Department of Medicine Solna, Stockholm, Sweden

Epidemiology

P035 Psoriasis and psoriatic arthritis among natives and mestizos from the Andean mountains region of Peru

Tolosa, Sergio¹; Vega-Hinojosa, Oscar²; Chandran, Vinod³; Valle-Oñate, Rafael⁴; Espinoza, Luis R.⁵

¹Hospital San Juan Bautista, Medicine, Catamarca, Argentina; ²Hospital III, Medicine, Juliaca, Peru; ³University of Toronto, Medicine, Toronto, Canada; ⁴Universidad de La Sabana, Medicine, Bogotá, Colombia; ⁵Louisiana State University, New Orleans, United States

P036 The Swedish Early Psoriatic Arthritis (SwePsA) registry. 5-year follow-up: worse outcomes for women compared to men.

Theander, Elke¹; Husmark, Tomas²; Alenius, Gerd-Marie³; Larsson, Per T⁴; Telemark, Annika⁵; Geijer, Mats⁶; Lindquist, Ulla R C⁷

¹Skåne University Hospital, Rheumatology, Malmö, Sweden; ²Falu Hospital, Rheumatology, Falun, Sweden; ³Umeå University Hospital, Public Health and Clinical Medicine, Umeå, Sweden; ⁴Karolinska University Hospital, Rheumatology, Stockholm, Sweden; ⁵Spenshult Rheumatological Hospital, Rheumatology, Oskarström, Sweden; ⁶Skånes University Hospital, Radiology, Lund, Sweden; ⁷Uppsala University Hospital, Medical Sciences, Rheumatology, Uppsala, Sweden

P037 Latent tuberculosis infection or tuberculin hiperergy? A three-year retrospective study on patients with psoriasis in an endemic area

Solovan, Caius¹; Chiticariu, Elena²; Stoia Dejka, Irina³

¹University of Medicine and Pharmacy "Victor Babes", Dermatology Department, Timisoara, Romania; ²County Hospital, Dermatology Clinic, Timisoara, Romania; ³Victor Babes Hospital, Pulmonology Clinic, Timisoara, Romania

P038 PSOLAR: Global update of a multicentre, open registry of psoriasis patients

Papp, Kim¹; Strober, Bruce²; Ho, V³; Binder, C⁴; Calabro, Steve⁵; Langhoff, Wayne⁶; Chevrier, Marc⁵

¹Probit Research, Waterloo, Canada; ²University of Connecticut, Department of Dermatology, Farmington, United States; ³University of British Columbia, Department of Dermatology and Skin Science, Vancouver, Canada; ⁴Janssen Inc, Toronto, Canada; ⁵Janssen Services, LLC, Horsham, United States; ⁶Janssen Research & Development, LLC, Horsham, United States

P039 Genital involvement in Indian patients with psoriasis

Muthu, Sendhil Kumaran; Mahajan, Rahul; Dogra, Sunil; Narang, Tarun; Handa, Sanjeev

Postgraduate Institute of Medical Education and Research, Dermatology, Venereology, Leprology, Chandigarh, India

P040 Advanced Cardiometabolic Phenotyping in Psoriasis: Links Between Psoriasis and Cardiovascular Disease?

Mehta, Nehal¹; Reilly, Muredach¹; Rader, Daniel¹; Mohler, Emile¹; Van-Voorhees, Abby²; Gelfand, Joel²

¹University of Pennsylvania, Cardiovascular Medicine, Philadelphia, United States; ²University of Pennsylvania, Dermatology, Philadelphia, United States

P041 Prevalence of doctor-diagnosed psoriasis and psoriatic arthritis in southern Sweden

Läfvendahl, Sofia¹; Theander, Elke²; Åke, Svensson³; Martin, Englund¹; Aleksandra, Turkiewicz¹; Petersson, Ingemar F¹

¹Clinical Sciences, Lund University, Lund, Dept. of Orthopedics, Lund, Sweden; ²Skåne University Hospital, Malmö, Dept. of Rheumatology, Malmö, Sweden; ³Skåne University Hospital, Malmö, Dept. of Dermatology, Malmö, Sweden

P042 Nail psoriasis: epidemiology and the burden of disease.

Klaassen, Karlijn; Pasch, Marcel; van de Kerkhof, Peter

Radboud University Nijmegen Medical Centre, Dermatology, Nijmegen, Netherlands

P043 Comparative analysis of the cohorts with early and established Psoriatic Arthritis (PsA).

Khraishi, Majed¹; Aslanov, Rana²

¹NEXUS Clinical Research, St. John's, Canada; ²Memorial University of Newfoundland, St. John's, NL, Canada

P044 Biologic therapies in the treatment of psoriasis: their association with the development of specific inflammatory comorbid conditions among a cohort of the Newfoundland and Labrador population

Gulliver, Wayne¹; Gladney, Neil²; Collins, Kayla²; Morrissey, Andrea²; MacDonald, Don²

¹Memorial University of Newfoundland, Faculty of Medicine, St. John's, NL, Canada; ²Newfoundland and Labrador Centre for Health Information, St. John's, NL, Canada

Abstract Titles continued

P045 An examination of biologic treatment groups of psoriasis patients in a cohort of the newfoundland and labrador population

Gulliver, Wayne¹; Morrissey, Andrea²; Gladney, Neil²; Dowden, Jeffrey²; Collins, Kayla²; Alaghebandan, Reza²; MacDonald, Don²

¹Memorial University of Newfoundland, Faculty of Medicine, St. John's, NL, Canada; ²Newfoundland and Labrador Centre for Health Information, St. John's, NL, Canada

P046 PSOLAR: Canadian update of a multicentre, open registry of psoriasis patients

Poulin, Y¹; Bissonnette, R²; Gulliver, W³; Guenther, L⁴; Lynde, C⁵; Ho, V⁶; Papp, Kim⁷; Binder, C⁸; Langhoff, Wayne⁹; Chevrier, Marc⁹

¹Centre Dermatologique du Quebec Metropolitain, Quebec City, Canada; ²Innovaderm, Montreal, Canada; ³Memorial University of Newfoundland, NewLab Clinical Research Inc, St. John's, Canada; ⁴Guenther Dermatology Research Centre, London, Canada; ⁵Lynde Dermatology, Markham, Canada; ⁶University of British Columbia, Department of Dermatology and Skin Science, Vancouver, Canada; ⁷Probit Medical Research, Waterloo, Canada; ⁸Janssen Inc, Toronto, Canada; ⁹Janssen Services, LLC, Horsham, United States

P047 Psoriatic Arthritis Mutilans in the Nordic countries; demographics and disease status

Gudbjornsson, Bjorn¹; Leif, Ejstrup²; Jan Tore, Gran³; Lars, Iversen⁴; Ulla, Lindqvist⁵; Leena, Paimela⁶; Thomas, TERNOWITZ⁷; Mona, Ståhle⁸

¹University Hospital, Center for Rheumatology Research, Reykjavik, Iceland; ²Odense University Hospital, Department of Rheumatology, Odense, Denmark; ³Oslo University Hospitals, Department of Rheumatology, Oslo, Norway; ⁴Aarhus University Hospital, Department of Dermatology, Aarhus, Denmark; ⁵Uppsala University, Department of Medical Sciences, Uppsala, Sweden; ⁶Helsinki University Central Hospital, Department of Rheumatology, Helsinki, Finland; ⁷Stavanger University Hospital, Department of Dermatology, Stavanger, Norway; ⁸Dermatology Unit, Department of Medicine, Karolinska Institutet Stockholm, Stockholm, Sweden

P048 Psoriasis- Epidemiology Characteristics and Patients' Quality of Life; Palestine 2011

Nazzal, Zaher; Arda, Hisham; Elaf, Abuzarour

An-Najah National University, Nablus, Palestinian Territory

P049 Natural course of psoriasis: A preliminary study

Alpsoy, Erkan¹; Donmez, Levent²; Nazlim, Berna¹; Ozkesici, Birgul¹; Akman-Karakas, Ayse¹; Yilmaz, Ertan¹

¹Akdeniz University, Dermatology and Venerology, Antalya, Turkey; ²Akdeniz University, Public Health, Antalya, Turkey

P050 Childhood psoriasis: characteristics of the disease among Saudi population

Alajlan, Abdulmajeed¹; Alsuwaidan, Sami²

¹King Khalid University Hospital, Dermatology, KKHU-Dermatology, Saudi Arabia; ²King Saud University, Dermatology, Riyadh, Saudi Arabia

Comorbidities

P051 Atherosclerosis in patients with psoriasis: role of systemic inflammation

Yeung, Chi Keung¹; Yiu, KH¹; Zhao, CT¹; Siu, CW¹; Tam, Sydney²; Wong, CS³; Yan, GHP³; Yue, WS³; Khong, PL³; Chan, Henry¹; Tse, HF¹

¹The University of Hong Kong, Medicine, Hong Kong, Hong Kong; ²The University of Hong Kong, Clinical Biochemistry, Hong Kong, Hong Kong; ³The University of Hong Kong, Diagnostic Radiology, Hong Kong, Hong Kong

P052 Considerations in the study of TNF-alpha inhibitor and methotrexate therapy on metabolic factors in psoriasis/psoriatic arthritis and rheumatoid arthritis patients

Wu, Jashin¹; Rowan, Christopher²; Poon, Kwun-Yee³; Anthony, Mary⁴; Xiang, Anny³

¹Kaiser Permanente Los Angeles Medical Center, Dermatology, Los Angeles, United States; ²Outcome, A Quintiles Company, Cambridge, United States; ³Kaiser Permanente Southern California, Department of Research and Evaluation, Pasadena, United States; ⁴Amgen Inc., Center for Observational Research, Thousand Oaks, United States

P054 Do TNF alpha-blockers influence male fertility?

Colsmann, Andreas; Kiesewetter, Franklin; Sticherling, Michael; Hautklinik Universitätsklinikum Erlangen, Erlangen, Germany

P055 Ophthalmic manifestations in psoriatic patients in a Brazilian referral center

Santos Paim de Oliveira, Maria de Fátima¹; de Oliveira Rocha, Bruno¹; Simas Yamakawa Boeira, Vanessa Lys¹; Abreu Azevedo Fraga, Naiara¹; Follador, Ivonise¹; Pedreira de Almeida Rêgo, Vitória Regina¹; de Oliveira Chagas, Ricardo Danilo²

¹Federal University of Bahia, Dermatology, Salvador, Brazil; ²Federal University of Bahia, Ophthalmology, Salvador, Brazil

P056 Vitamin D, body fat composition and parameters of atherogenesis and inflammation in psoriatic patients treated with narrow-band UVB

Romani, Jorge¹; Caixás, Assumpta²; Ceperuelo, Victoria³; Carrascosa, José M.⁴; Ribera, Miquel¹; Rigla, Mercedes²; Vendrell, Joan³; Luelmo, Jesús¹

¹Hospital Parc Taulí, Dermatology, Sabadell Barcelona, Spain; ²Hospital Parc Taulí, Endocrinology, Sabadell Barcelona, Spain; ³Hospital Joan XXIII, Endocrinology, Tarragona, Spain; ⁴Hospital Germans Trias i Pujol, Dermatology, Badalona, Spain

P057 Adipocytokine expression and correlation with atherogenesis and inflammation markers in psoriatic patients treated with narrow-band UVB phototherapy

Romani, Jorge¹; Caixás, Assumpta²; Ceperuelo, Victoria³; Carrascosa, José M.⁴; Ribera, Miquel¹; Rigla, Mercedes²; Luelmo, Jesús¹

¹Hospital Parc Taulí, Dermatology, Sabadell Barcelona, Spain; ²Hospital Parc Taulí, Endocrinology, Sabadell Barcelona, Spain; ³Hospital Joan XXIII, Endocrinology, Tarragona, Spain; ⁴Hospital Germans Trias i Pujol, Dermatology, Badalona, Spain

P058 Prevalence of metabolic syndrome in psoriatic patients

RAVELLA MATEU, ANNA¹; Albareda, M.²; Castelló, M.²; Saborit, S²; Roqué, M²; Peramiqúel, L.³; Smanđia, JA¹; Vila, LL.⁴

¹HOSPITAL DOS DE MAIG, DERMATOLOGY, BARCELONA, Spain; ²Hospital Moises Broggi, Endocrinology, S. Joan Despi, Spain; ³Hospital Moises Broggi, Dermatology, S. Joan Despi, Spain; ⁴Moises Broggi, Endocrinology, S. Joan Despi, Spain

P059 Use of brachial-ankle index for assessing cardiovascular risk in patients with psoriatic arthritis, psoriasis alone and controls: a pilot study

Magro-Checa, César¹; Rosales-Alexander, José Luis¹; Orgaz-Molina, Jacinto²; Salvatierra, Juan¹; Arias-Santiago, Salvador²; Cantero-Hinojosa, Jesús¹; Ruiz-Carrascosa, José Carlos²; Raya-Álvarez, Enrique¹

¹San Cecilio University Hospital, Rheumatology, Granada, Spain; ²San Cecilio University Hospital, Psoriasis Unit, Dermatology, Granada, Spain

P060 Cardiovascular risk assessment in patients with psoriatic arthritis: comparison of european SCORE and two calibrated national guidelines

Magro-Checa, César; Rosales-Alexander, José Luis; Salvatierra, Juan; Cantero-Hinojosa, Jesús; Sánchez-Parera, Ricardo; Montes-García, Silvia; González-Domínguez, José; Raya-Álvarez, Enrique

San Cecilio University Hospital, Rheumatology, Granada, Spain

P061 Psoriasis and psoriatic arthritis: Large waist circumference and severity assessment

Kogan, Nora¹; Gusic, Simon²; Veira, Rosana¹; Crespo, Alejandra¹; Chaparro, Elena¹; Amabile, Pilar¹; Kreimer, Jennifer¹; Castelli, Andrea²; Montoya, Sandra²; Kerzberg, Eduardo²

¹Ramos Mejia Hospital, Dermatology, Buenos Aires, Argentina; ²Ramos Mejia Hospital, Rheumatology, Buenos Aires, Argentina

P062 Psoriasis and psoriatic arthritis: Body Mass Index and severity assessment

Kogan, Nora¹; Gusic, Simon²; Veira, Rosana¹; Crespo, Alejandra¹; Chaparro, Elena¹; Amabile, Pilar¹; Kreimer, Jennifer¹; Castelli, Andrea²; Montoya, Sandra²; Kerzberg, Eduardo²

¹Ramos Mejia Hospital, Dermatology, Buenos Aires, Argentina; ²Ramos Mejia Hospital, Rheumatology, Buenos Aires, Argentina

P063 Psoriasis and cardiovascular screening rates in the United States

Gustafson, Cheryl¹; Alamdari, Habibollah¹; Davis, Scott¹; Huang, William¹; Feldman, Steve¹

Wake Forest University, Department of Dermatology, Winston-Salem, United States

P064 Association of renal cancer in a psoriasis cohort from the Newfoundland and Labrador founder population

Gulliver, Wayne¹; Gladney, Neil²; Collins, Kayla²; Morrissey, Andrea²; MacDonald, Don²

¹Memorial University of Newfoundland, Faculty of Medicine, St. John's, NL, Canada; ²Newfoundland and Labrador Centre for Health Information, St. John's, NL, Canada

P065 Risk of developing cancer among psoriasis patients as compared to non-psoriasis patients

Gulliver, Wayne¹; Gladney, Neil²; Collins, Kayla²; Morrissey, Andrea²; MacDonald, Don²

¹Memorial University of Newfoundland, Faculty of Medicine, St. John's, NL, Canada; ²Newfoundland and Labrador Centre for Health Information, St. John's, NL, Canada

P066 Association between pediatric psoriasis and the metabolic syndrome

Goldminz BA, Ari¹; Au MD, Shiu-Chung¹; Kim MD, Noori¹; Loo MD, Daniel¹; Dumont, Nicole¹; Levine MD, Danielle¹; Lizzul MD PhD MBA MPH, Paul¹; Volf MD, Eva¹; Michelin MD, Melissa¹; Wang MD, Andrew¹; Yaniv BA, Shimrat¹; Kerensky MD, Todd¹; Brown MD, Mary²; Kulig MD MPH, John²; Lopez-Benitez MD, Jorge²; Natter MD, Mark²; Miller MD, Laurie²; Pelajo MD MSc, Christina²; Davis MD, Trevor²; Gottlieb MD PhD, Alice¹

¹Tufts Medical Center, Dermatology, Boston, United States; ²Tufts Medical Center, Pediatrics, Boston, United States

P067 Coronary risk estimation and other cardiovascular comorbidities in moderate to severe psoriasis patients in Spain. RECOR study

García-Calvo, Carmen

Pfizer España, S.L.U., Medical Department, Madrid, Spain

P068 Association between systemic anti-psoriatic drugs and cardiovascular risk in patients with psoriasis and psoriatic arthritis: a nationwide cohort study

Chen, Yi-Ju¹; Chang, Yun-Ting²; Shen, Jui-Lung³; Chen, Tzu-Ting³; Wang, Chang-Bi⁴; Chen, Chuan-Mu⁵; Wu, Chun-Ying²

¹Taichung Veterans General Hospital, Department of Dermatology, Taichung, Taiwan; ²National Yang-Ming University, Taipei, Taiwan; ³Taichung Veterans General Hospital, Taichung, Taiwan; ⁴China Medical University, Taichung, Taiwan; ⁵National Chung-Hsing University, Taichung, Taiwan

P069 The use of ustekinumab in a patient with severe psoriasis and positive HBV serology

Steglich, Raquel¹; Carvalho, André VE¹; Cheinquer, Hugo²; Meneghello, Luana¹; Müller, Fernanda¹

¹Irmandade da Santa Casa de Misericórdia de Porto Alegre, Dermatology, Porto Alegre, Brazil; ²Irmandade da Santa Casa de Misericórdia de Porto Alegre, Hepatology, Porto Alegre, Brazil

P070 Prevalence of overweight/obesity in psoriasis population and its therapeutic consequences in clinical setting. Experience from Biobadaderm

Carrascosa, Jose-Manuel¹; Vilavella, Marta²; Garcia-Doval, Ignacio³; Ferrandiz, Carlos¹; Rivera, Raquel⁴; Carretero, Gregorio⁵; Dauden, Esteban⁶; Herrera, Enrique⁷; Alsina, Merce⁸; Ferran, Marta⁹; Lopez-Esteban, Jose-Luis¹⁰; Gomez, Francisco¹¹; Hernanz, Jose-Manuel¹²; Vanaclocha, Francisco⁴; Biobadaderm, group¹³

¹Hospital Universitario Germans trias i pujol, Dermatology, Badalona, Spain; ²Hospital Germans Trias i Pujol, Dermatology, Badalona, Spain; ³Unidad de Investigación Academia Española de Dermatología, Madrid, Spain; ⁴Hospital 12 de Octubre, Dermatology, Madrid, Spain; ⁵Hospital Juan Negrin, Dermatology, Las Palmas, Spain; ⁶Hospital de la Princesa, Dermatology, Madrid, Spain; ⁷Hospital Universitario de Málaga, Dermatology, Málaga, Spain; ⁸Hospital Clínic i Provincial, Dermatology, Barcelona, Spain; ⁹Hospital del Mar, Dermatology, Barcelona, Spain; ¹⁰Hospital Infanta Leonor, Dermatology, Madrid, Spain; ¹¹Hospital Universitario Reina Sofía, Dermatology, Cordoba, Spain; ¹²Hospital Alcorcon, Dermatology, Madrid, Spain; ¹³AEDV, Madrid, Spain

Current and new therapeutic modalities

P071 Management of severe cases of psoriasis: some interesting cases

XIAO, Ting

The First Affiliated Hospital of China Medical University, Dermatology, Shenyang, China

P072 Successful treatment of generalized pustular psoriasis in an 8 year old male with infliximab

Skrabl- Baumgartner, Andrea¹; Salmhofer, Wolfgang²; Muntean, Wolfgang³; Weger, Wolfgang²

¹Medical University of Graz, Pediatric Department, Graz, Austria; ²Medical University of Graz, Department of Dermatology, Graz, Austria; ³Medical University of Graz, Pediatric Department, Graz, Austria

P073 A randomized, double-blind, placebo-controlled study of ustekinumab in Chinese patients with moderate to severe plaque psoriasis: LOTUS trial results

Zheng, M¹; Zhu, X²; Song, M³; Shen, Y-K³; Wang, B⁴

¹Second Affiliated Hospital, Zhejiang University School of Medicine, Dept of Dermatology, Hangzhou, China; ²Peking University First Hospital, Department of Dermatology and Venereology, Beijing, China; ³Janssen Research & Development LLC, Spring House, United States; ⁴Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, China

P074 Efficacy and safety of secukinumab (a fully human anti-interleukin-17A antibody) in a phase II regimen-finding study for the treatment of moderate-to-severe plaque psoriasis

Rich, PA¹; Sigurgeirsson, B²; Guettner, A³; Machacek, M³; Papavassilis, C³

¹Oregon Dermatology and Research Center, Portland, United States; ²University of Iceland, Department of Dermatology, Reykjavik, Iceland; ³Novartis Pharma AG, Basel, Switzerland

Abstract Titles continued

P075 Recombinant bacterial system for local delivery of anti-TNF α biomolecules

Ravnikar, Matjaz¹; Berlec, Ales²; Obermajer, Natasa²; Lunder, Mojca¹; Strukelj, Borut¹

¹Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia;
²Jozef Stefan Institute, Ljubljana, Slovenia

P076 Psoriasis patients required to discontinue adalimumab therapy have worsening in their quality of life out of proportion to worsening in the objective signs of disease: subanalysis of REVEAL

Poulin, Yves¹; Sheth, Pranav²; Gu, Yihua³; Okun, Martin³

¹Centre Dermatologique du Quebec Metropolitain, Québec, Canada;
²Group Health Associates, Trihealth, Cincinnati, United States; ³Abbott Laboratories, Abbott Park, United States

P077 Phase IIa randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase (JAK) inhibitor, in patients with moderate-to-severe psoriasis

Papp, Kim¹; Pariser, David²; Wierz, Gina³; Ball, Greg³; Akinlade, Bola³; Zeiher, Bernhard³

¹Probit Medical Research, East Waterloo, Canada; ²Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, United States; ³Astellas Pharma Global Development, Inc., Deerfield, United States

P078 Improvement of psoriasis in subjects with and without prior brodalumab (AMG 827) treatment in an open-label extension study

Papp, Kim¹; Leonardi, Craig²; Menter, Alan³; Ortonne, Jean-Paul⁴; Klekotka, Paul⁵; Aras, Girish⁵; Thompson, Elizabeth⁵; Lin, Shao-Lee⁵; Kricorian, Gregory⁵

¹Probit Medical Research, Waterloo ON, Canada; ²St Louis University, St Louis, United States; ³Baylor University Medical Center, Dallas, United States; ⁴Hopital de l'Archet, Nice, France; ⁵Amgen Inc, Thousand Oaks, United States

P079 Long term efficacy and safety of ustekinumab in patients with moderate to severe psoriasis through 5 years of follow-up: results from the PHOENIX 1 long-term extension

Papp, Kim¹; Kimball, A²; Wasfi, Y³; Chan, D³; Bissonnette, R⁴; Sofen, H⁵; Yeilding, N³; Li, S³; Szapary, P³; Gordon, K⁶

¹Probit Medical Research, Waterloo, Canada; ²Harvard Medical School and Massachusetts General Hospital, Boston, United States; ³Janssen Research & Development, LLC, Spring House, United States; ⁴Innovaderm Research, Inc, Montreal, Canada; ⁵Dermatology Research Associates, Los Angeles, United States; ⁶North Shore University Health System and University of Chicago Pritzker School of Medicine, Chicago, United States

P080 Secukinumab for treatment of moderate-to-severe plaque psoriasis: results of a phase II dose-ranging study

Papp, K¹; Sigurgeirsson, B²; Haemmerle, S³; Richards, H³; Papavasiliu, C³

¹Probit Medical Research, Ontario, Canada; ²University of Iceland, Reykjavik, Iceland; ³Novartis Pharma AG, Basel, Switzerland

P081 Novel EP₄ antagonists as a new therapy for auto-immune diseases

Okumura, Takako; Kanazawa, Kiyoshi; Takahashi, Nobuyuki; Take, Yukinori

RaQualia Pharma Inc., Research, Aichi, Japan

P082 Serendipity opens new avenues; A pilot study to evaluate the efficacy of saxagliptin in combination with cyclosporine and acitretin in diabetic psoriasis patients

Narang, Tarun¹; Dogra, Sunil²; Handa, Sanjeev²

¹Post Graduate Institute of Medical Education and research, Dermatology, Venereology and Leprology, Chandigarh, India; ²Post Graduate Institute of Medical Education and Research, Chandigarh, India, Dermatology, Venereology and Leprology, Chandigarh, India

P083 Secukinumab, a fully human anti-interleukin-17A antibody, improves signs and symptoms of psoriatic arthritis: A 24-week, double-blind, placebo-controlled, multicenter trial

McInnes, I¹; Sieper, J²; Braun, J³; Emery, P⁴; van der Heijde, D⁵; Isaacs, J⁶; Dahmen, G⁷; Wollenhaupt, J⁸; Schulze-Koops, H⁹; Gsteiger, S¹⁰; Bertolino, A.P.¹¹; Hueber, W¹¹; Tak, P.P.¹²

¹University of Glasgow, Glasgow, United Kingdom; ²Charite` Campus Benjamin Franklin, Berlin, Germany; ³Rheumazentrum Ruhrgebiet, Herne, Germany; ⁴University of Leeds, NIHR-Leeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, Leeds, United Kingdom; ⁵Leiden University Medical Center, Leiden, Netherlands; ⁶Newcastle University and the Freeman Hospital, Newcastle-upon-Tyne, United Kingdom; ⁷Praxis fuer klinische Studien, Hamburg, Germany; ⁸Eilbeck Hospital, Hamburg, Germany; ⁹Klinikum Innenstadt der Ludwig-Maximilians-Universitat, Munich, Germany; ¹⁰Novartis Pharma AG, Basel, Switzerland; ¹¹Novartis Institutes for BioMedical Research, Basel, Switzerland; ¹²University of Amsterdam, Amsterdam, Netherlands

P084 Combined treatment of psoriasis with methotrexate and narrowband UVB phototherapy compared with methotrexate alone and narrowband UVB alone

Mashhadani, Sabeeh; Al-Hamamy, Haider; Nazar, Ihsan

College of Medicine/Baghdad University, Dermatology, Baghdad, Iraq

P085 Treatment in mono-oligo- and polyarthritic patients; a 5 year study on the Swedish early psoriatic arthritis cohort (SwePsA)

Lindqvist, Ulla Ruth Kristina¹; Husmark, Tomas²; Alenius, Gerd-Marie³; Larsson, P T⁴; Telemann, Annika⁵; Geijer, Mats⁶; Theander, E⁷

¹Department of Medical Sciences, Rheumatology, Uppsala, Sweden; ²Department of Rheumatology, Falu Hospital, Falun, Sweden; ³Dept of Public Health and Clinical Medicine, Rheumatology, University of Umeå, Umeå, Sweden; ⁴Department of Rheumatology, Karolinska University Hospital Huddinge, Huddinge, Sweden; ⁵Spenshult Hospital, Oskarström, Sweden; ⁶Center of medical imaging and physiology, Lund University, Lund, Sweden; ⁷Department of Rheumatology, Skåne University Hospital, Malmö, Sweden

P086 Content validity of a novel patient-reported psoriasis symptom diary for patients with moderate-to-severe plaque psoriasis

Lebwohl, Mark¹; Nyirady, J²; Gwaltney, C.J.³; Strober, B.E.⁴

¹The Mount Sinai School of Medicine, New York, United States; ²Novartis Pharmaceuticals Corporation, East Hanover, United States; ³PRO Consulting, Pittsburgh, United States; ⁴University of Connecticut, Farmington, United States

P087 Safety and efficacy of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis

Lebwohl, Mark G.¹; Kircik, Leon²; Callis Duffin, Kristina³; Pariser, David⁴; Hooper, Michele⁵; Wenkert, Deborah⁵; Thompson, Elizabeth HZ⁵; Yang, Jun⁵; John, Koo⁶

¹Mount Sinai Medical Center, New York, NY, United States; ²Derm Research, PLLC, Louisville, KY, United States; ³University of Utah, Salt Lake City, UT, United States; ⁴Virginia Clinical Research, Inc., Norfolk, VA, United States; ⁵Amgen Inc., Thousand Oaks, CA, United States; ⁶University of California at San Francisco, San Francisco, CA, United States

P088 Secukinumab for treatment of moderate-to-severe plaque psoriasis: Results of a double-blind, parallel-group, placebo-controlled, phase II dose ranging study

kumari, Nishi

Novartis, Hyderabad, India

P089 Our experience with naphtalan therapy in danish psoriasis patients

Krnjevic Pezic, Gordana¹; Pasic, Aida²; Ceovic, Romana²; Stanimirovic, Andrija³; Ivkovic, Jakov¹; Ceovic, Romana²

¹Naftalan, Special Hospital for Medical rehabilitation, Ivanic - Grad, Croatia; ²Zagreb University Hospital Center, Dermatology and Venerology, Zagreb, Croatia; ³School of Health Studies, Zagreb, Croatia

P090 Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate to severe palmoplantar psoriasis

Kim MD, Noori; Au MD, Shiu-Chung; Goldminz, Ari; Dumont, Nicole; Michelon MD, Melissa; Volf MD, Eva; Hession MD, Meghan; Lizzul MD PhD MBA MPH, Paul; Andrews MD, Israel; Kerensky MD, Todd; Wang MD, Andrew; Yaniv, Shimrat; Gottlieb MD PhD, Alice

Tufts Medical Center, Dermatology, Boston, United States

P091 Ustekinumab in patients with active psoriatic arthritis: results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study

McInnes, I¹; Kavanaugh, A²; Gottlieb, A³; Puig, L⁴; Rahman, P⁵; Ritchlin, C⁶; Li, S⁷; Wang, Y⁸; Mendelsohn, A⁷; Doyle, M⁸

¹University of Glasgow, Glasgow, United Kingdom; ²University of California-San Diego, La Jolla, United States; ³Tufts Medical Center, Boston, United States; ⁴Universitat Autònoma de Barcelona, Barcelona, Spain; ⁵Memorial University, Newfoundland, Canada; ⁶University of Rochester, Rochester, United States; ⁷Janssen Research & Development, LLC, Spring House, United States; ⁸Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, United States

P093 ASP015K: A novel JAK inhibitor demonstrated potent efficacy in a chronic oxazolone-induced dermatitis model in rats

Higashi, Yasuyuki¹; Inami, Masamichi¹; Ito, Misato¹; Chida, Noboru¹; Nakanishi, Tomonori²; Ooshima, Shinsuke¹; Hanaoka, Kaori¹; Ookubo, Keiko³; Shirakami, Shohei⁴; Inoue, Takayuki⁴; Fujii, Yasutomo⁵; Yamazaki, Shunji⁵

¹Pharmacology Research Labs, Astellas Pharma Inc., Ibaraki, Japan; ²Astellas Research Institute of America LLC, Skokie, United States; ³Astellas Research Technology Co., Ltd., Osaka, Japan; ⁴Chemistry Research Labs, Astellas Pharma Inc., Ibaraki, Japan; ⁵Applied Pharmacology Research Labs, Astellas Pharma Inc., Ibaraki, Japan

P094 Efficacy and safety of topical combination treatments in chronic plaque psoriasis: A systematic literature review

Hendriks, Anke; Keijsers, Romy; de Jong, Elke; Seyger, Marieke; van de Kerkhof, Peter

Radboud University Nijmegen Medical Centre, Dermatology, Nijmegen, Netherlands

P095 Psoriasis treatment expectations and healthcare provider relationships for patients in Europe, the USA and Canada

Hansen, Mikkel¹; Bewley, Anthony²; Ersser, Steven³; Ward, Corinne⁴

¹LEO Pharma A/S, Corporate Medical Affairs, Ballerup, Denmark; ²Whipps Cross University Hospital, Dermatology Service, London, United Kingdom; ³University of Hull, Faculty of Health and Social Care, Hull, United Kingdom; ⁴Mater Dei Hospital, Administration Department, Msida, Malta

P097 Use of modern psychometric techniques to demonstrate improvement in fatigue in RA patients treated with secukinumab

Gnanasakthy, A.¹; Kosinski, M.²; Durez, P.³; Mallya, U.G.¹; Mpofo, S.⁴

¹Novartis Pharmaceuticals Corporation, East Hanover, United States; ²Quality Metric Incorporated, Lincoln, RI, United States; ³Université Catholique de Louvain, Brussels, Belgium; ⁴Novartis Pharma AG, Basel, Switzerland

P098 Association between reduction in disease activity, pain severity and health-related quality of life (HRQoL) among rheumatoid arthritis (RA) patients treated with secukinumab

Gnanasakthy, A.¹; Kosinski, M.²; Genovese, M.³; Mallya, U.G.¹; Mpofo, S.⁴

¹Novartis Pharmaceuticals Corporation, East Hanover, United States; ²Quality Metric Incorporated, Lincoln, RI, United States; ³Stanford University School of Medicine, California, United States; ⁴Novartis Pharma AG, Basel, Switzerland

P099 Evaluation of high and low intensity physical functioning in secukinumab treated RA patients: an application of IRT methodology

Gnanasakthy, A.¹; Kosinski, M.²; Kellner, H.³; Mallya, U.G.¹; Mpofo, S.⁴

¹Novartis Pharmaceuticals Corporation, East Hanover, United States; ²QualityMetric Incorporated, Lincoln, United States; ³Praxis München Nymphemburg, Germany, Germany; ⁴Novartis Pharma AG, Basel, Switzerland

P100 Etanercept in psoriasis and psoriatic arthritis: an Indian experience

Ghosh, Sanjay¹; Prasad, Balaram²

¹MGM Medical College & LSK Hospital, Department of Dermatology, Kishanganj, India; ²Institute of Allergic & Immunologic Skin Diseases, Department of Dermatology & Internal Medicine, Kolkata, India

P101 Secukinumab improves signs and symptoms in patients with active rheumatoid arthritis: results of dose-finding, double blind, randomized, placebo controlled, phase II study

Genovese, Mark¹; Durez, Patrick²; Richards, Hanno³; Supronik, Jerzy⁴; Dokoupilova, Eva⁵; Aelion, Jacob A.⁶; Lee, Sang-Heon⁷; Codding, Christine E.⁸; Kellner, Herbert⁹; Ikawa, Takashi¹⁰; Hugot, Sophie⁹; Ligozio, Gregory¹¹; Mpofo, Shephard³

¹Stanford University, Palo Alto, Canada; ²Université Catholique de Louvain, Brussels, Belgium; ³Novartis Pharma AG, Basel, Swaziland; ⁴NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland; ⁵Medical Plus s.r.o, Uherske Hradiste, Czech Republic; ⁶Arthritis Clinic, Jackson, Tanzania; ⁷Konkuk University Medical Center, Seoul, Republic of Korea; ⁸Health Research of Oklahoma, Oklahoma, United States; ⁹Centre for Inflammatory Joint Diseases, Munich, Germany; ¹⁰Kobe-Konan Yamate Clinic, Kobe, Japan; ¹¹Novartis Pharmaceuticals Corporation, East Hanover, United States

P102 Effect of secukinumab treatment on ACR50, HAQ-DI and EULAR remission rates in patients with Rheumatoid Arthritis

Genovese, Mark¹; Kellner, Herbert²; Durez, Patrick³; Codding, Christine E.⁴; Ligozio, Gregory⁵; Richards, Hanno B.⁶; Escrig, Cesar⁶; Mpofo, Shephard⁶

¹Stanford University, Palo Alto, United States; ²Centre for Inflammatory Joint Diseases, Munich, Germany; ³Université Catholique de Louvain, Brussels, Belgium; ⁴Health Research of Oklahoma, Oklahoma City, United States; ⁵Novartis Pharmaceuticals Corporation, East Hanover, United States; ⁶Novartis Pharma AG, Basel, Switzerland

P103 Maintenance therapy of psoriasis with cyclosporine: comparison between continuous and weekend therapy

Fernandes, Iolanda¹; Torres, Tiago²; Selores, Manuela²

¹Centro Hospitalar do Porto - Hospital de Santo António, Dermatology, Porto, Portugal; ²Centro Hospitalar do Porto - Hospital de Santo António, Porto, Portugal

Abstract Titles continued

P104 Formulation of anthralin in liquid solution for the treatment of scalp psoriasis

Farshi, Susan¹; Farshi, Hooman²; Saghazadeh, Mojgan³

¹Tehran University of Medical Sciences, Dermatology, Tehran, Islamic Republic of Iran; ²Azad University, Chemistry, Tehran, Islamic Republic of Iran; ³Qom Branch, Islamic Azad University, Microbiology, Tehran, Islamic Republic of Iran

P105 Secukinumab induces higher assessment of spondyloarthritis international society responses over placebo in patients with moderate-to-severe ankylosing spondylitis: results of 28-week, double blind, randomized, placebo-controlled trial

Emery, Paul¹; Baeten, D²; Sieper, J³; Braun, J⁴; van der Heijde, D⁵; McInnes, P⁶; van Laar, J⁷; Landewe, R⁸; Wordsworth, P⁹; Wollenhaupt, J¹⁰; Kellner, H¹¹; Paramarta, J¹; Bertolino, A¹²; Gsteiger, S¹³; Wright, A¹³; Hueber, W¹²

¹University of Leeds, Department of Medicine, Leeds, United Kingdom; ²University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands; ³Charite Campus Benjamin Franklin, Department of Gastroenterology, Berlin, Germany; ⁴Rheumazentrum Ruhrgebiet, Department of Medicine, Herne, Germany; ⁵Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands; ⁶University of Glasgow, Glasgow Biomedical Research Centre, Glasgow, United Kingdom; ⁷Newcastle University, Department of Medicine, Newcastle upon Tyne, United Kingdom; ⁸Maastricht University Medical Center, Department of Medicine, Maastricht, Netherlands; ⁹Nuffield Orthopaedic Centre, Department of Medicine, Oxford, United Kingdom; ¹⁰Eilbeck Hospital, Hamburg, Klinik für Rheumatologie, Hamburg, Germany; ¹¹Centre for Inflammatory Joint Diseases, Department of Medicine, Munich, Germany; ¹²Novartis Institutes for BioMedical Research, TM Dermatology, Basel, Switzerland; ¹³Novartis Pharma AG, M&S Statistics, Basel, Switzerland

P106 Secukinumab treatment has no effect on the lipid profile in patients with rheumatoid arthritis: results from a randomized, double-blind, placebo-controlled, phase II study

Durez, Patric¹; Genovese, M²; Kellner, H³; Codding, C⁴; Ligozio, G⁵; Richards, H⁶; Escrig, C⁶; Mpoju, S⁶

¹Cliniques Universitaires Saint-Luc, Tour Pasteur, Belgium; ²Stanford University, California, United States; ³Centre for Inflammatory Joint Diseases, Munich, Germany; ⁴Health Research of Oklahoma, Oklahoma, United States; ⁵Novartis Pharmaceuticals Corporation, East Hanover, United States; ⁶Novartis Pharma AG, Basel, Switzerland

P107 Phototherapy of psoriasis in the era of biologics: our experience

Ceovic, Romana; Kostovic, Kresimir; Bukvic Mocos, Zrinka; Stulhofer Buzina, Daska; Drvar Ledic, Daniela; Basta Juzbasic, Aleksandra

University Hospital Center Zagreb and School of Medicine University of Zagreb, Department of Dermatology and Venerology, Zagreb, Croatia

P108 Utilization of narrow-band UVB light therapy and Etanercept for the treatment of psoriasis/characteristics of PASI responders

Belas, Monica

Hospital Nacional De Clinicas, Cordoba, Argentina

P109 Secukinumab reduces spinal inflammation as early as week 6 in patients with ankylosing spondylitis, as detected by magnetic resonance imaging – results of a double-blind, placebo-controlled, multicenter phase II proof-of-concept study

Baraliakos, X¹; Braun, J¹; Laurent, D²; Baeten, D³; van der Heijde, D⁴; Sieper, J⁵; Emery, P⁶; McInnes, I⁷; van Laar, J⁸; Landewe, R⁹; Wordsworth, P¹⁰; Wollenhaupt, J¹¹; Kellner, H¹²; Wright, M¹³; Gsteiger, S¹³; Hueber, W²

¹Rheumazentrum Ruhrgebiet, Herne, Germany; ²Novartis Institutes for BioMedical Research, Basel, Switzerland; ³Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; ⁴Leiden University Medical Center, Leiden, Netherlands; ⁵Charite Campus Benjamin Frank-

lin, Berlin, Germany; ⁶University of Leeds, Leeds, United Kingdom; ⁷University of Glasgow, Glasgow, United Kingdom; ⁸Newcastle University, Newcastle upon Tyne, United Kingdom; ⁹Maastricht University Medical Center, Maastricht, Netherlands; ¹⁰Nuffield Orthopaedic Centre, Oxford, United Kingdom; ¹¹Eilbeck Hospital, Hamburg, Germany; ¹²Centre for Inflammatory Joint Diseases, Munich, Germany; ¹³Novartis Pharma AG, Basel, Switzerland

P111 Wnt pathway inhibitors in patients with psoriatic and rheumatoid arthritis treated with anti-TNF therapy

Szentpetery, Agnes¹; Bhattoa, Harjit Pal²; Antal-Szalmás, Peter²; Szekanez, Zoltan³; FitzGerald, Oliver¹

¹St. Vincent's University Hospital, Rheumatology, Dublin, Ireland; ²Medical and Health Science Center University of Debrecen, Laboratory Medicine, Debrecen, Hungary; ³Medical and Health Science Center University of Debrecen, Rheumatology, Debrecen, Hungary

P112 Serum IL-23 does not correlate with disease activity in psoriatic arthritis and SAPHO syndrome

Przepiera-Bezdek, Hanna; Brzosko, Iowna; Fischer, Katarzyna; Brzosko, Marek

Pomeranian Medical University in Szczecin, Department of Rheumatology and Internal Diseases, Szczecin, Poland

P113 Molecular signature and new perspective markers of psoriasis

Mezentsev, Alexandre¹; Sobolev, Vladimir²; Soboleva, Anna²; Bruskin, Sergey²

¹Institute of General Genetics, Functional Genomics, Moscow, Russian Federation; ²Institute of General Genetics, Functional Genetics, Moscow, Russian Federation

P114 Altered microRNA expression in peripheral blood mononuclear cells from patients with psoriasis

Loevidorf, Marianne B.¹; Zibert, John R.¹; Marstrand, Troels¹; Glue, Christian²; Ødum, Niels³; Roepke, Mads A.⁴; Skov, Lone⁵

¹LEO Pharma A/S, Molecular Biomedicine, Ballerup, Denmark; ²Exiqon A/S, Vedbaek, Denmark; ³University of Copenhagen, Department of International Health, Immunology & Microbiology, Faculty of Health Sciences, Copenhagen, Denmark; ⁴LEO Pharma A/S, Medical Department, Ballerup, Denmark; ⁵Gentofte Hospital, Dermato-allergology, Hellerup, Denmark

P115 Clinical examination versus magnetic resonance imaging of the hand and foot: its usefulness in early detection of psoriatic arthritis among patients with psoriasis

Korotaeva, Tatiana¹; Krasnenko, Svetlana²; Loginova, Elena¹; Goryachev, Dmitriy³; Smirnov, Alexander²

¹Research Institute of Rheumatology, Laboratory of Seronegative Spondyloarthritis, Moscow, Russian Federation; ²Research Institute of Rheumatology, Radiology, Moscow, Russian Federation; ³Research Institute of Rheumatology, Laboratory of Medico-Social Investigations, Moscow, Russian Federation

P116 The relative activity of anti-TNF- α agents, etanercept, infliximab, adalimumab and golimumab, evaluated by a stable IL-8 reporter cell line, THP-G8

Kimura, Yutaka; Takahashi, Toshiya; Yamasaki, Kenshi; Aiba, Setsuya

Tohoku University Graduate School of Medicine, Department of Dermatology, Sendai, Japan

P117 Predictive biomarkers for high responsiveness to treatment, and biomarkers associated with clinical response to treatment, in psoriasis patients treated with the anti-IL-17A monoclonal antibody, ixekizumab

Hoffman, Robert¹; Krueger, James²; Fretzin, Scott³; Dow, Ernst¹; Nantz, Eric¹; Komocsar, Wendy¹; Cameron, Gregory¹; Phipps, Krista¹; McCollm, Juliet¹; Banerjee, Subhashis¹

¹Eli Lilly and Company, Indianapolis, United States; ²Rockefeller University, New York, United States; ³Dawes-Fretzin Dermatology Group, Indianapolis, United States

P118 The Swedish Early Psoriatic Arthritis (SwePsA) Registry 5-year follow-up: Slow radiographic progression of bone destruction in the hands without correlation to clinical disease activity

Geijer, Mats¹; Lindqvist, Ulla²; Husmark, Tomas³; Alenius, Gerd-Marie⁴; Larsson, Per T⁵; Teleman, Annika⁶; Theander, Elke⁷

¹Skåne University Hospital, Lund, Center for Medical Imaging and Physiology, Lund, Sweden; ²Uppsala University, Rheumatology, Department Of Medical Sciences, Uppsala, Sweden; ³Falu Hospital, Rheumatology, Falun, Sweden; ⁴Umeå University, Public Health and Clinical Medicine/Rheumatology, Umeå, Sweden; ⁵Karolinska University Hospital Huddinge, Rheumatology, Stockholm, Sweden; ⁶Spenshult AB, Oskarstrom, Sweden; ⁷Skåne University Hospital, Rheumatology, Malmö, Sweden

P119 A screening tool that includes key clinical features and biomarkers discriminates patients with psoriatic arthritis (PsA) from those with psoriasis without PsA

Chandran, Vinod¹; Cook, Richard²; Lee, Ker-Ai²; Pellett, Fawnda¹; Gladman, Dafna¹

¹Toronto Western Hospital, Division of Rheumatology, Toronto, Canada; ²University of Waterloo, Department of Statistics and Actuarial Science, Waterloo, Canada

P120 Treg profile of psoriasis patients - preliminary data

Boca, Andreea; Tataru, Alexandru; Orasan, Remus; Krausz, Tibor; Buzoianu, Anca

University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania, Cluj-Napoca, Romania

P121 Health-Related Quality Of Life (HRQOL) improvement with secukinumab in patients with rheumatoid arthritis: results from a dose-finding study

Vibeke, Strand¹; Genovese, M²; Mallya, UG³; Richards, H⁴; Mpfu, S⁴

¹Stanford University, Division of Immunology/Rheumatology, Portola Valley, Canada; ²Stanford University School of Medicine, California, United States; ³Novartis Pharmaceuticals Corporation, East Hanover, United States; ⁴Novartis Pharma AG, Basel, Switzerland

P122 Use of clinical trial data to compare psoriasis area and severity index, static physician's global assessment, and lattice system-physician's global assessment in assessing severity of psoriasis

Tejasvi, Trilokraj¹; Chow, Conroy¹; Simpson, Matthew J.²; Ellis, Charles N.¹

¹University of Michigan Medical School, Department of Dermatology, Ann Arbor, Michigan, United States; ²University of Michigan School of Public Health, Department of Epidemiology, Ann Arbor, Michigan, United States

P123 Psychiatric disorders in psoriatic patients in Semnan city during the first six months of 2006: a survey.

Taheri, Ramin¹; Behnam, Behnaz²

¹Fatemie hospital/Semnan University of Medical Science, Internal Medicine, Semnan, Islamic Republic of Iran; ²Fatemie hospital/Semnan University of Medical Science, Psychiatry, Semnan, Islamic Republic of Iran

P125 Significant effects of patient educative training on psoriasis disease

Kling, Heidrun; Jahn, Julia; Sticherling, Michael

Hautklinik Universitätsklinikum Erlangen, Erlangen, Germany

P126 Percentage of suicidal ideation and suicidal attempts in adult patients diagnosed with psoriasis

Sison, Antonio; Verallo-Rowell, Vermén

Skin and Cancer Foundation, Inc, Dermatology, Pasig City, Philippines

P127 A descriptive study on the knowledge and beliefs of adult patients diagnosed with psoriasis

Sison, Antonio; Verallo-Rowell, Vermén

Skin and Cancer Foundation, Inc, Dermatology, Pasig City, Philippines

P128 Quality of life and health-state utilities in psoriasis patients

Pan, Jiun Yi; Theng, Colin; Tan, Suat Hoon

National Skin Centre, Singapore

P129 The psoriatic school, education for patients with psoriasis, psoriatic arthritis and pustulosis palmoplantaris

Naslund, Anja¹; Stymne, Birgitta²; Stiernquist, Anne¹

¹The Swedish Psoriasis Association, Stockholm, Sweden; ²University Hospital Linköping, Dermatology department, Linköping, Sweden

P130 Perceived disadvantages in leisure time activities among patients with psoriasis

Leino, M¹; Mattila, K¹; Mustonen, A¹; Koulu, L¹; Tuominen, R²

¹Turku University Hospital, Dermatology, Turku, Finland; ²University of Turku, Public Health, Turku, Finland

P131 Quality-of-life effects of psoriasis skin symptoms affecting different body regions

Kimball, Alexa B.¹; Sundaram, Murali²; Signorovitch, James³; Yang, Min³; Mulani, Parvez M.²

¹Harvard Medical School, Department of Dermatology, Boston, MA, United States; ²Abbott Laboratories, Global Health Economics and Outcomes Research, Abbott Park, IL, United States; ³Analysis Group, Inc., Boston, MA, United States

P132 The use of an Apple iPad-based® Health Assessment Questionnaire (HAQ) application in psoriatic and rheumatoid arthritis

Khraishi, Majed; Aslanov, Rana

Newfoundland Labrador Research Technologies, St. John's, Canada

P133 Psoriasis - a model for chronic diseases in dermatology

Gupta, Monisha¹; Gupta, Monisha²

¹Skin and Cancer Foundation Australia, NSW, Strathfield, Australia; ²Skin and Cancer Foundation Australia, NSW, Darlinghurst, Australia

P134 Association between ACR improvement and health-related quality of life (HRQoL) among rheumatoid arthritis (RA) patients treated with secukinumab

Gnanasakthy, A¹; Kosinski, M²; Genovese, M³; Mallya, UG¹; Mpfu, S⁴

¹Novartis Pharmaceuticals Corporation, East Hanover, United States; ²QualityMetric Incorporated, Lincoln, United States; ³Stanford University School of Medicine, California, United States; ⁴Novartis Pharma AG, Basel, Switzerland

P135 Sex-specific differences in health-related quality of life in patients with moderate to severe psoriasis

Cather, Jennifer C.¹; Horn, Elizabeth J.²; Sundaram, Murali³; Bao, Yanjun³

¹Modern Dermatology, a Baylor Health Texas Affiliate, and Modern Research Associates, Dallas, TX, United States; ²Modern Research Associates, Dallas, TX, United States; ³Abbott Laboratories, Global Health Economics and Outcomes Research, Abbott Park, IL, United States

P136 Sex differences in health-related quality of life in patients with moderate to severe psoriasis

Cather, Jennifer C.¹; Horn, Elizabeth J.²; Sundaram, Murali³; Yang, Min⁴; Farooqui, Saif³; Mulani, Parvez M.³

¹Modern Dermatology, a Baylor Health Texas Affiliate, and Modern Research Associates, Dallas, Texas, United States; ²Modern Research Associates, Dallas, Texas, United States; ³Abbott Laboratories, Global Health Economics and Outcomes Research, Abbott Park, IL, United States; ⁴Analysis Group, Inc., Boston, MA, United States

Abstract Titles continued

P137 Colors of psoriasis: The lived experiences of middle aged adults with moderate to severe psoriasis

Bustos, John Patrick¹; Burgos, Gem Angeli²; Burgos, Mikaela³; Butic, Kiel Lara⁴; Caballes, Ana Angela⁵; Caboboy, Jessica Louise⁶; Maravilla, Susan²

¹University of Santo Tomas, Manila, Nursing, Angeles city, Philippines;

²University of Santo Tomas, Manila, Nursing, Manila, Philippines;

³University of Santo Tomas, Manila, Nursing, Novaliches, Philippines;

⁴University of Santo Tomas, Manila, Nursing, Ifugao, Philippines; ⁵University of Santo Tomas, Manila, Nursing, Rizal, Philippines; ⁶University of Santo Tomas, Manila, Nursing, Quezon, Philippines

P138 The global challenge of stigmatization and discrimination for people with psoriasis: Preliminary results of a survey carried out by the International Federation of Psoriasis Associations and 15 national member associations

Bohannan, Barbra¹; Gallant, Kathleen²

¹IFPA, Stockholm, Sweden; ²IFPA Executive Committee/Chair of IFPA Task Force on NCDs Committee, Pittsburgh, United States

P139 Psoriasis Uncovered: The results of two quantitative surveys of psoriasis patients in Australia

Baker, Christopher; Foley, Peter; Braue, Anna

Skin and Cancer Foundation Inc, Carlton, Australia

P140 Erectile dysfunction: a rare side effect of methotrexate

Yayli, Savah; Akban, Burak; Aksu Arýca, Deniz; Bahadýr, Sevgi

Karadeniz Technical University School of Medicine, Department of Dermatology, Trabzon, Turkey

P141 Anti-TNF-alpha treatment in a psoriatic patient with concurrent HCV infection

Santos Paim de Oliveira, Maria de Fátima; de Oliveira Rocha, Bruno; Follador, Ivonise; Pedreira de Almeida Régo, Vitória Regina

Federal University of Bahia, Dermatology, Salvador, Brazil

P142 Tinea capitis in two sisters of a “wooly hair” family

Ozyurt, Kemal; Ozturk, Perihan; Karakas, Tugba; Dokur, Neslihan

KSU Medicine Faculty, Dermatology, Kahramanmaras, Turkey

P143 Concurrent of progressive macular hypomelanosis and port-wine stain nevus in the same patient

Ozturk, Perihan; Ozyurt, Kemal; Dokur, Neslihan

KSU Medicine Faculty, Dermatology, Kahramanmaras, Turkey

P144 Together of progressive macular hypomelanosis and port-wine stain nevus in the same patient

Ozturk, Perihan; Ozyurt, Kemal; Dokur, Neslihan

KSU Medicine Faculty, Dermatology, Kahramanmaras, Turkey

P145 A case of multiple cutaneous leishmaniasis cured with intramuscular sodium stibogluconate

Ozturk, Perihan; Ozyurt, Kemal; Dokur, Neslihan; Karakas, Tugba

KSU Medicine Faculty, Dermatology, Kahramanmaras, Turkey

P146 Successful treatment of a paradoxical palmoplantar pustulosis with ustekinumab in a patient with psoriatic arthritis

Morales Múnica, Caridad Elena; López Ferrer, Anna; Puig Sanz, Lluís
Hospital de la Santa Creu i Sant Pau, Dermatology, Barcelona, Spain

P147 Annular pustular psoriasis in a patient with pemphigus foliaceus

Kato, Kenichi; Tatsumi, Motohiro; Takahashi, Yuji; Yamanaka, Takashi

Kansai Rosai Hospital, Department of Dermatology, Amagasaki city, Hyogo Prefecture, Japan

P148 Psoriatic arthritis and Degos diseases: a clinical case

landoli, Raffaele

S. G. Moscati Hospital, Dermatology, Avellino, Italy

P149 Coexisting of psoriasis and lupus erythematosus: A diagnostic and therapeutic challenges

Elsherif, Nadia A¹; Elmatardi, Marada A¹; Eldahumi, Ahlam S²; Elman-gush, Ibtisam M¹

¹Benghazi university, dermatology department, Benghazi, Libyan Arab

Jamahiriya; ²Jamhoria hospital, dermatology department, Benghazi,

Libyan Arab Jamahiriya

P150 Successful treatment of a patient with undifferentiated connective tissue disease and psoriasis with ustekinumab

Brown-Maher, Tracey; Astani, Roxanna; Gulliver, Wayne

Memorial University of Newfoundland, Faculty of Medicine, St. John's, NL, Canada

P151 Cost of psoriasis and psoriatic arthritis in Denmark

Sætterstrøm, Bjørn¹; Gniadecki, Robert²; Kragballe, Knud³; Zachariae, Claus⁴; Lindkvist, Rose-Marie⁵; Qvitzau, Susanne⁶; Olsen, Jens¹

¹University of Southern Denmark, Centre for Applied Health Services Research and Technology Assessment (CAST), Odense, Denmark;

²Bispebjerg Hospital, Department of Dermatology, Copenhagen, Den-

mark; ³Aarhus University Hospital, Department of Dermatology, Aarhus,

Denmark; ⁴Gentofte Hospital, Department of Dermatology, Copenhagen,

Denmark; ⁵Pfizer, Medical and Access, Ballerup, Denmark; ⁶Pfizer,

Medical, Ballerup, Denmark

P152 One-year cost-effectiveness analysis of etanercept vs. adalimumab for moderate-to-severe plaque psoriasis

Ruano, Juan¹; Isla-Tejera, Beatriz²; Jiménez-Puya, Rafael¹; Cárdenas, Manuel³; Gómez, Francisco¹; Velez Garcia-Nieto, Antonio¹; Del Prado-Llargo, Jose-Ramón²; Moreno-Giménez, Jose-Carlos¹

¹Reina Sofia University Hospital, Department of Dermatology, Córdoba,

Spain; ²Reina Sofia University Hospital, Department of Pharmacy,

Córdoba, Spain

P153 Impact of psoriasis on work performance

Mattila, Kalle¹; Leino, Mauri¹; Koulu, Leena¹; Tuominen, Risto²

¹University Hospital, Turku, Dermatology, Turku, Finland; ²University of Turku, Department of Public Health, Turku, Finland

P154 Important of psoriasis severity index in social-medical expertise

Chijavadze, Nino¹; Tsagareishvili, Konstantine²; Datuashvili, Maia¹

¹Psoriasis Association of Georgia - PSO Georgia, Dermatology, Kutaisi,

Georgia; ²Psoriasis Association of Georgia - PSO Georgia, Kutaisi,

Georgia

P155 Studying the calcium serum level in patients suffering from psoriasis

Goldust, Mohamad

Tabriz University of medical sciences, Tabriz, Islamic Republic of Iran



INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS

FOR 125 MILLION PEOPLE - HERE'S HOPE!

**THANK YOU FOR JOINING US FOR THE 3RD
WORLD PSORIASIS & PSORIATIC ARTHRITIS
CONFERENCE AND FOR ALL YOUR HARD WORK
AND EFFORTS TOWARD HELPING PEOPLE
WITH PSORIASIS ALL OVER THE WORLD!**



Learn more about IFPA and our
projects on www.ifpa-pso.org.

under the
spotlight





























Photo:Ola Ericson/imagebank.sweden.se (Rosendal's Garden, Djurgården), Conny Fridh/imagebank.sweden.se (Steamer in Stockholm Archipelago – one of few historical steamboats in traffic), Ola Ericson/imagebank.sweden.se (Night in "Gamla stan", the Old Town in Stockholm, the street dates back to the 1300), Erik G Svensson/Stockholm Visitors Board (Offshore race outside Old Town), Ola Ericson/imagebank.sweden.se (Hills of Södermalm, one of the innercity neighborhoods), Ola Ericson/imagebank.sweden.se (Haga Echo temple. Hagaparken in Stockholm is a part of the worlds first National citypark.)



THE STAR ALLIANCE NETWORK WELCOMES YOU TO STOCKHOLM

We are pleased to be the official airline network for this event and we hope your participation in the 3rd World Psoriasis & Psoriatic Arthritis Conference 2012 is a successful one.

- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 

The 3rd World Psoriasis & Psoriatic Arthritis
Conference 2012 is presented by
the International Federation of Psoriasis Associations, IFPA



INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS

and supported by



Official airline



STAR ALLIANCE
THE WAY THE EARTH CONNECTS



Welcome to IFPA



Worldwide unity for people
living with psoriasis



INTERNATIONAL FEDERATION
OF PSORIASIS ASSOCIATIONS